Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,7864421,TOF ratio,TOF ratio was significantly lower after priming with 20 micrograms/kg at the fifth and sixth minutes (0.59 +/- 0.29 and 0.56 +/- 0.32; mean +/- 1 SD) compared with the first minute (0.95 +/- 0.1).,"Pharmacodynamics, pharmacokinetics, and intubation conditions after priming with three different doses of vecuronium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7864421/),,0.59,1449,DB01339,Vecuronium
,7864421,TOF ratio,TOF ratio was significantly lower after priming with 20 micrograms/kg at the fifth and sixth minutes (0.59 +/- 0.29 and 0.56 +/- 0.32; mean +/- 1 SD) compared with the first minute (0.95 +/- 0.1).,"Pharmacodynamics, pharmacokinetics, and intubation conditions after priming with three different doses of vecuronium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7864421/),,0.56,1450,DB01339,Vecuronium
,7864421,TOF ratio,TOF ratio was significantly lower after priming with 20 micrograms/kg at the fifth and sixth minutes (0.59 +/- 0.29 and 0.56 +/- 0.32; mean +/- 1 SD) compared with the first minute (0.95 +/- 0.1).,"Pharmacodynamics, pharmacokinetics, and intubation conditions after priming with three different doses of vecuronium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7864421/),,0.95,1451,DB01339,Vecuronium
,7864421,Recovery index,"Recovery index was significantly increased after priming with 20 micrograms/kg (13.2 +/- 6.6 min, P < 0.05) compared with 10 micrograms/kg (9.2 +/- 4.8 min) and 15 micrograms/kg (6.7 +/- 1.5 min).","Pharmacodynamics, pharmacokinetics, and intubation conditions after priming with three different doses of vecuronium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7864421/),min,13.2,1452,DB01339,Vecuronium
,7864421,Recovery index,"Recovery index was significantly increased after priming with 20 micrograms/kg (13.2 +/- 6.6 min, P < 0.05) compared with 10 micrograms/kg (9.2 +/- 4.8 min) and 15 micrograms/kg (6.7 +/- 1.5 min).","Pharmacodynamics, pharmacokinetics, and intubation conditions after priming with three different doses of vecuronium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7864421/),min,9.2,1453,DB01339,Vecuronium
,7864421,Recovery index,"Recovery index was significantly increased after priming with 20 micrograms/kg (13.2 +/- 6.6 min, P < 0.05) compared with 10 micrograms/kg (9.2 +/- 4.8 min) and 15 micrograms/kg (6.7 +/- 1.5 min).","Pharmacodynamics, pharmacokinetics, and intubation conditions after priming with three different doses of vecuronium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7864421/),min,6.7,1454,DB01339,Vecuronium
,8678276,Peak serum IFCs,Peak serum IFCs were higher with sevoflurane (34.5 mumol/l) than with enflurane (19.4 mumol/l).,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [l],34.5,8706,DB01339,Vecuronium
,8678276,Peak serum IFCs,Peak serum IFCs were higher with sevoflurane (34.5 mumol/l) than with enflurane (19.4 mumol/l).,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [l],19.4,8707,DB01339,Vecuronium
,8678276,area under the curve (AUC),The area under the curve (AUC) was greater with sevoflurane (688 mumol/l.h) than with enflurane (591 mumol/l.h).,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [h·l],688,8708,DB01339,Vecuronium
,8678276,area under the curve (AUC),The area under the curve (AUC) was greater with sevoflurane (688 mumol/l.h) than with enflurane (591 mumol/l.h).,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [h·l],591,8709,DB01339,Vecuronium
,8678276,peak serum IFCs,In our study 1.69 MAC-h sevoflurane produced peak serum IFCs of 34.5 mumol/l.,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [l],34.5,8710,DB01339,Vecuronium
,16931668,onset of action,"The onset of action in the IT group (127 +/- 17 s) was significantly earlier than that in the IM group (267 +/- 62 s), and significantly later than that in the IV group (18 +/- 7 s) (P < 0.05 by analysis of variance and the Tukey-Kramer analysis).","The efficacy of intratracheal administration of vecuronium in rats, compared with intravenous and intramuscular administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16931668/),s,127,17904,DB01339,Vecuronium
,16931668,onset of action,"The onset of action in the IT group (127 +/- 17 s) was significantly earlier than that in the IM group (267 +/- 62 s), and significantly later than that in the IV group (18 +/- 7 s) (P < 0.05 by analysis of variance and the Tukey-Kramer analysis).","The efficacy of intratracheal administration of vecuronium in rats, compared with intravenous and intramuscular administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16931668/),s,267,17905,DB01339,Vecuronium
,16931668,onset of action,"The onset of action in the IT group (127 +/- 17 s) was significantly earlier than that in the IM group (267 +/- 62 s), and significantly later than that in the IV group (18 +/- 7 s) (P < 0.05 by analysis of variance and the Tukey-Kramer analysis).","The efficacy of intratracheal administration of vecuronium in rats, compared with intravenous and intramuscular administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16931668/),s,18,17906,DB01339,Vecuronium
,16931668,duration of action,The duration of action in the IT group (794 +/- 162 s) was significantly longer than that in the IV group (93 +/- 30 s) but not significantly different from that in the IM group (743 +/- 131 s).,"The efficacy of intratracheal administration of vecuronium in rats, compared with intravenous and intramuscular administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16931668/),s,794,17907,DB01339,Vecuronium
,16931668,duration of action,The duration of action in the IT group (794 +/- 162 s) was significantly longer than that in the IV group (93 +/- 30 s) but not significantly different from that in the IM group (743 +/- 131 s).,"The efficacy of intratracheal administration of vecuronium in rats, compared with intravenous and intramuscular administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16931668/),s,93,17908,DB01339,Vecuronium
,16931668,duration of action,The duration of action in the IT group (794 +/- 162 s) was significantly longer than that in the IV group (93 +/- 30 s) but not significantly different from that in the IM group (743 +/- 131 s).,"The efficacy of intratracheal administration of vecuronium in rats, compared with intravenous and intramuscular administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16931668/),s,743,17909,DB01339,Vecuronium
,16931668,recovery index,The recovery index in the IT group (134 +/- 30 s) was significantly shorter than that in the IM group (222 +/- 47 s) and significantly longer than that in the IV group (32 +/- 12 s).,"The efficacy of intratracheal administration of vecuronium in rats, compared with intravenous and intramuscular administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16931668/),s,134,17910,DB01339,Vecuronium
,16931668,recovery index,The recovery index in the IT group (134 +/- 30 s) was significantly shorter than that in the IM group (222 +/- 47 s) and significantly longer than that in the IV group (32 +/- 12 s).,"The efficacy of intratracheal administration of vecuronium in rats, compared with intravenous and intramuscular administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16931668/),s,222,17911,DB01339,Vecuronium
,16931668,recovery index,The recovery index in the IT group (134 +/- 30 s) was significantly shorter than that in the IM group (222 +/- 47 s) and significantly longer than that in the IV group (32 +/- 12 s).,"The efficacy of intratracheal administration of vecuronium in rats, compared with intravenous and intramuscular administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16931668/),s,32,17912,DB01339,Vecuronium
,6119998,ED50,The ED50 of neostigmine (dose which produced a 50% antagonism) when antagonizing Org NC 45 and pancuronium was 0.011 mg kg-1 and 0.010 mg kg-1 respectively.,Antagonism of org NC 45 (vecuronium) and pancuronium neuromuscular blockade by neostigmine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119998/),[mg] / [kg],0.011,18027,DB01339,Vecuronium
,6119998,ED50,The ED50 of neostigmine (dose which produced a 50% antagonism) when antagonizing Org NC 45 and pancuronium was 0.011 mg kg-1 and 0.010 mg kg-1 respectively.,Antagonism of org NC 45 (vecuronium) and pancuronium neuromuscular blockade by neostigmine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119998/),[mg] / [kg],0.010,18028,DB01339,Vecuronium
,6107104,distribution half-life,The pharmacokinetics could be described using a two-compartment open model with a distribution half-life of approximately 4 min and an elimination half-life of approximately 31 min.,Pharmacokinetics and pharmacodynamics of Org NC 45 in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6107104/),min,4,18299,DB01339,Vecuronium
,6107104,elimination half-life,The pharmacokinetics could be described using a two-compartment open model with a distribution half-life of approximately 4 min and an elimination half-life of approximately 31 min.,Pharmacokinetics and pharmacodynamics of Org NC 45 in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6107104/),min,31,18300,DB01339,Vecuronium
,6107104,steady-state plasma concentration,The mean steady-state plasma concentration producing a 50% block of the twitch response was 0.137 microgram ml-1 (range 0.118--0.176 microgram ml-1).,Pharmacokinetics and pharmacodynamics of Org NC 45 in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6107104/),[μg] / [ml],0.137,18301,DB01339,Vecuronium
,11573664,elimination half-life,"The elimination half-life of vecuronium was significantly reduced in both anticonvulsant groups compared with control [control 48.2 (SD 40.3), phenytoin 23.5 (13.1), carbamazepine 18.4 (16.6) min, P<0.05].",Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573664/),min,48.2,21612,DB01339,Vecuronium
,11573664,elimination half-life,"The elimination half-life of vecuronium was significantly reduced in both anticonvulsant groups compared with control [control 48.2 (SD 40.3), phenytoin 23.5 (13.1), carbamazepine 18.4 (16.6) min, P<0.05].",Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573664/),min,23.5,21613,DB01339,Vecuronium
,11573664,elimination half-life,"The elimination half-life of vecuronium was significantly reduced in both anticonvulsant groups compared with control [control 48.2 (SD 40.3), phenytoin 23.5 (13.1), carbamazepine 18.4 (16.6) min, P<0.05].",Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573664/),min,18.4,21614,DB01339,Vecuronium
,11573664,clearance,"Vecuronium clearance was increased in both anticonvulsant groups [control 9.0 (3.6), phenytoin 15.1 (8.9), carbamazepine 18.8 (13.1) ml kg(-1) min(-1), 0.05<P<0.1].",Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573664/),[ml] / [kg·min],9.0,21615,DB01339,Vecuronium
,11573664,clearance,"Vecuronium clearance was increased in both anticonvulsant groups [control 9.0 (3.6), phenytoin 15.1 (8.9), carbamazepine 18.8 (13.1) ml kg(-1) min(-1), 0.05<P<0.1].",Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573664/),[ml] / [kg·min],15.1,21616,DB01339,Vecuronium
,11573664,clearance,"Vecuronium clearance was increased in both anticonvulsant groups [control 9.0 (3.6), phenytoin 15.1 (8.9), carbamazepine 18.8 (13.1) ml kg(-1) min(-1), 0.05<P<0.1].",Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573664/),[ml] / [kg·min],18.8,21617,DB01339,Vecuronium
,11573664,RI,"Children on chronic anticonvulsant therapy had a significantly shorter RI than control [control 21.8 (11), phenytoin 12.5 (8.3), carbamazepine 10.6 (5.9) min, P<0.05].",Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573664/),min,21.8,21618,DB01339,Vecuronium
,11573664,RI,"Children on chronic anticonvulsant therapy had a significantly shorter RI than control [control 21.8 (11), phenytoin 12.5 (8.3), carbamazepine 10.6 (5.9) min, P<0.05].",Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573664/),min,12.5,21619,DB01339,Vecuronium
,11573664,RI,"Children on chronic anticonvulsant therapy had a significantly shorter RI than control [control 21.8 (11), phenytoin 12.5 (8.3), carbamazepine 10.6 (5.9) min, P<0.05].",Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573664/),min,10.6,21620,DB01339,Vecuronium
,2886080,plasma clearance,"For vecuronium, plasma clearance (3.7 +/- 1.0 and 5.2 +/- 0.8 ml X kg-1 X min-1, respectively), and volume of distribution at steady-state (179 +/- 31 and 244 +/- 38 ml X kg-1, respectively) were lower in the elderly than in young adults; values for distribution half-lives, elimination half-life, and sensitivity of the neuromuscular junction were similar for the two groups.",Pancuronium and vecuronium pharmacokinetics and pharmacodynamics in younger and elderly adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886080/),[ml] / [kg·min],3.7,36689,DB01339,Vecuronium
,2886080,plasma clearance,"For vecuronium, plasma clearance (3.7 +/- 1.0 and 5.2 +/- 0.8 ml X kg-1 X min-1, respectively), and volume of distribution at steady-state (179 +/- 31 and 244 +/- 38 ml X kg-1, respectively) were lower in the elderly than in young adults; values for distribution half-lives, elimination half-life, and sensitivity of the neuromuscular junction were similar for the two groups.",Pancuronium and vecuronium pharmacokinetics and pharmacodynamics in younger and elderly adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886080/),[ml] / [kg·min],5.2,36690,DB01339,Vecuronium
,2886080,volume of distribution at steady-state,"For vecuronium, plasma clearance (3.7 +/- 1.0 and 5.2 +/- 0.8 ml X kg-1 X min-1, respectively), and volume of distribution at steady-state (179 +/- 31 and 244 +/- 38 ml X kg-1, respectively) were lower in the elderly than in young adults; values for distribution half-lives, elimination half-life, and sensitivity of the neuromuscular junction were similar for the two groups.",Pancuronium and vecuronium pharmacokinetics and pharmacodynamics in younger and elderly adults. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886080/),[ml] / [kg],179,36691,DB01339,Vecuronium
,2886080,volume of distribution at steady-state,"For vecuronium, plasma clearance (3.7 +/- 1.0 and 5.2 +/- 0.8 ml X kg-1 X min-1, respectively), and volume of distribution at steady-state (179 +/- 31 and 244 +/- 38 ml X kg-1, respectively) were lower in the elderly than in young adults; values for distribution half-lives, elimination half-life, and sensitivity of the neuromuscular junction were similar for the two groups.",Pancuronium and vecuronium pharmacokinetics and pharmacodynamics in younger and elderly adults. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886080/),[ml] / [kg],244,36692,DB01339,Vecuronium
,9579494,half-lives,"The mean half-lives of equilibration between plasma and the effect compartments to inhibit T1 and T4 were 2.5 and 3.2 min, respectively.",Pharmacokinetic analysis of the effect of vecuronium in surgical patients: pharmacokinetic and pharmacodynamic modeling without plasma concentrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579494/),min,2.5,37309,DB01339,Vecuronium
,9579494,half-lives,"The mean half-lives of equilibration between plasma and the effect compartments to inhibit T1 and T4 were 2.5 and 3.2 min, respectively.",Pharmacokinetic analysis of the effect of vecuronium in surgical patients: pharmacokinetic and pharmacodynamic modeling without plasma concentrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579494/),min,3.2,37310,DB01339,Vecuronium
,9579494,half-lives of distribution,"The mean half-lives of distribution and elimination from the central compartment were 7.7 and 7.8 min, respectively.",Pharmacokinetic analysis of the effect of vecuronium in surgical patients: pharmacokinetic and pharmacodynamic modeling without plasma concentrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579494/),min,7.7,37311,DB01339,Vecuronium
,9579494,elimination from the central compartment,"The mean half-lives of distribution and elimination from the central compartment were 7.7 and 7.8 min, respectively.",Pharmacokinetic analysis of the effect of vecuronium in surgical patients: pharmacokinetic and pharmacodynamic modeling without plasma concentrations. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579494/),min,7.8,37312,DB01339,Vecuronium
,20876699,T₄/T₁ ratio,The primary efficacy variable was time from the start of sugammadex administration to recovery of T₄/T₁ ratio to 0.9.,Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20876699/),,0.9,40194,DB01339,Vecuronium
,20876699,recovery times of T₄/T₁ ratio,"A statistically significant dose-response relationship was demonstrated for mean recovery times of T₄/T₁ ratio to 0.9 with increasing sugammadex dose with both NMBAs: rocuronium, 96.3 min (placebo) to 1.5 min (sugammadex 4.0 mg kg⁻¹); vecuronium, 79.0 min (placebo) to 3.0 min (sugammadex 4.0 mg kg⁻¹).",Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20876699/),min,0.9,40195,DB01339,Vecuronium
,20876699,recovery times of T₄/T₁ ratio,"A statistically significant dose-response relationship was demonstrated for mean recovery times of T₄/T₁ ratio to 0.9 with increasing sugammadex dose with both NMBAs: rocuronium, 96.3 min (placebo) to 1.5 min (sugammadex 4.0 mg kg⁻¹); vecuronium, 79.0 min (placebo) to 3.0 min (sugammadex 4.0 mg kg⁻¹).",Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20876699/),min,96.3,40196,DB01339,Vecuronium
,20876699,recovery times of T₄/T₁ ratio,"A statistically significant dose-response relationship was demonstrated for mean recovery times of T₄/T₁ ratio to 0.9 with increasing sugammadex dose with both NMBAs: rocuronium, 96.3 min (placebo) to 1.5 min (sugammadex 4.0 mg kg⁻¹); vecuronium, 79.0 min (placebo) to 3.0 min (sugammadex 4.0 mg kg⁻¹).",Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20876699/),min,1.5,40197,DB01339,Vecuronium
,20876699,recovery times of T₄/T₁ ratio,"A statistically significant dose-response relationship was demonstrated for mean recovery times of T₄/T₁ ratio to 0.9 with increasing sugammadex dose with both NMBAs: rocuronium, 96.3 min (placebo) to 1.5 min (sugammadex 4.0 mg kg⁻¹); vecuronium, 79.0 min (placebo) to 3.0 min (sugammadex 4.0 mg kg⁻¹).",Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20876699/),min,79.0,40198,DB01339,Vecuronium
,20876699,recovery times of T₄/T₁ ratio,"A statistically significant dose-response relationship was demonstrated for mean recovery times of T₄/T₁ ratio to 0.9 with increasing sugammadex dose with both NMBAs: rocuronium, 96.3 min (placebo) to 1.5 min (sugammadex 4.0 mg kg⁻¹); vecuronium, 79.0 min (placebo) to 3.0 min (sugammadex 4.0 mg kg⁻¹).",Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20876699/),min,3.0,40199,DB01339,Vecuronium
,2877596,volume of distribution at steady state (Vdss),The volume of distribution at steady state (Vdss) was greater (P less than 0.05) after vecuronium (320 +/- 181 ml/kg; mean +/- SD) than after pancuronium (203 +/- 36 ml/kg).,Pharmacokinetics and pharmacodynamics of vecuronium and pancuronium in anesthetized children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877596/),[ml] / [kg],320,42725,DB01339,Vecuronium
,2877596,volume of distribution at steady state (Vdss),The volume of distribution at steady state (Vdss) was greater (P less than 0.05) after vecuronium (320 +/- 181 ml/kg; mean +/- SD) than after pancuronium (203 +/- 36 ml/kg).,Pharmacokinetics and pharmacodynamics of vecuronium and pancuronium in anesthetized children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877596/),[ml] / [kg],203,42726,DB01339,Vecuronium
,2877596,Plasma clearance,Plasma clearance of vecuronium (2.8 +/- 0.9 ml X min-1 X kg-1) was greater than that of pancuronium (1.7 +/- 0.2 ml X min-1 X kg-1; P less than 0.05).,Pharmacokinetics and pharmacodynamics of vecuronium and pancuronium in anesthetized children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877596/),[ml] / [kg·min],2.8,42727,DB01339,Vecuronium
,2877596,Plasma clearance,Plasma clearance of vecuronium (2.8 +/- 0.9 ml X min-1 X kg-1) was greater than that of pancuronium (1.7 +/- 0.2 ml X min-1 X kg-1; P less than 0.05).,Pharmacokinetics and pharmacodynamics of vecuronium and pancuronium in anesthetized children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877596/),[ml] / [kg·min],1.7,42728,DB01339,Vecuronium
,9422901,volume of the central compartment,"The mean volume of the central compartment and volume of distribution at steady state were 42.3 (SD 11.8) ml kg-1 and 168.4 (31.5) ml kg-1, respectively, in control patients, and significantly greater (55.2 (13.4) ml kg-1 and 225.9 (53.3) ml kg-1) in the haemodilution patients (P < 0.05).",Pharmacokinetics of vecuronium during acute isovolaemic haemodilution. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422901/),[ml] / [kg],42.3,44250,DB01339,Vecuronium
,9422901,volume of the central compartment,"The mean volume of the central compartment and volume of distribution at steady state were 42.3 (SD 11.8) ml kg-1 and 168.4 (31.5) ml kg-1, respectively, in control patients, and significantly greater (55.2 (13.4) ml kg-1 and 225.9 (53.3) ml kg-1) in the haemodilution patients (P < 0.05).",Pharmacokinetics of vecuronium during acute isovolaemic haemodilution. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422901/),[ml] / [kg],55.2,44251,DB01339,Vecuronium
,9422901,volume of distribution at steady state,"The mean volume of the central compartment and volume of distribution at steady state were 42.3 (SD 11.8) ml kg-1 and 168.4 (31.5) ml kg-1, respectively, in control patients, and significantly greater (55.2 (13.4) ml kg-1 and 225.9 (53.3) ml kg-1) in the haemodilution patients (P < 0.05).",Pharmacokinetics of vecuronium during acute isovolaemic haemodilution. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422901/),[ml] / [kg],168.4,44252,DB01339,Vecuronium
,9422901,volume of distribution at steady state,"The mean volume of the central compartment and volume of distribution at steady state were 42.3 (SD 11.8) ml kg-1 and 168.4 (31.5) ml kg-1, respectively, in control patients, and significantly greater (55.2 (13.4) ml kg-1 and 225.9 (53.3) ml kg-1) in the haemodilution patients (P < 0.05).",Pharmacokinetics of vecuronium during acute isovolaemic haemodilution. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422901/),[ml] / [kg],225.9,44253,DB01339,Vecuronium
,9422901,elimination half-life,The elimination half-life was 50.3 (11.5) min in control patients and significantly greater (68.2 (15.1) min) in the haemodilution patients (P < 0.05).,Pharmacokinetics of vecuronium during acute isovolaemic haemodilution. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422901/),min,50.3,44254,DB01339,Vecuronium
,9422901,elimination half-life,The elimination half-life was 50.3 (11.5) min in control patients and significantly greater (68.2 (15.1) min) in the haemodilution patients (P < 0.05).,Pharmacokinetics of vecuronium during acute isovolaemic haemodilution. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422901/),min,68.2,44255,DB01339,Vecuronium
,12081155,apparent distribution volumes,"The apparent distribution volumes of patients A and B were 1.43 and 1.62 l/kg, respectively.",Pharmacokinetics of propofol in elderly coronary artery bypass graft patients under total intravenous anesthesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12081155/),[l] / [kg],1.43,46489,DB01339,Vecuronium
,12081155,apparent distribution volumes,"The apparent distribution volumes of patients A and B were 1.43 and 1.62 l/kg, respectively.",Pharmacokinetics of propofol in elderly coronary artery bypass graft patients under total intravenous anesthesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12081155/),[l] / [kg],1.62,46490,DB01339,Vecuronium
,12081155,half-lives,"The half-lives of propofol in the plasma of patients A and B were estimated to be 13.3 and 17.4 min as the a phase, and 10.1 and 10.5 h as the beta phase, respectively.",Pharmacokinetics of propofol in elderly coronary artery bypass graft patients under total intravenous anesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12081155/),min,13.3,46491,DB01339,Vecuronium
,12081155,half-lives,"The half-lives of propofol in the plasma of patients A and B were estimated to be 13.3 and 17.4 min as the a phase, and 10.1 and 10.5 h as the beta phase, respectively.",Pharmacokinetics of propofol in elderly coronary artery bypass graft patients under total intravenous anesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12081155/),min,17.4,46492,DB01339,Vecuronium
,12081155,half-lives,"The half-lives of propofol in the plasma of patients A and B were estimated to be 13.3 and 17.4 min as the a phase, and 10.1 and 10.5 h as the beta phase, respectively.",Pharmacokinetics of propofol in elderly coronary artery bypass graft patients under total intravenous anesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12081155/),h,10.1,46493,DB01339,Vecuronium
,12081155,half-lives,"The half-lives of propofol in the plasma of patients A and B were estimated to be 13.3 and 17.4 min as the a phase, and 10.1 and 10.5 h as the beta phase, respectively.",Pharmacokinetics of propofol in elderly coronary artery bypass graft patients under total intravenous anesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12081155/),h,10.5,46494,DB01339,Vecuronium
,6132566,clearance,Vecuronium had a more rapid clearance (5.2 +/- 0.7 ml X kg-1 X min-1; mean +/- SD) and a shorter elimination half-life (71 +/- 20 min) as compared with pancuronium (1.8 +/- 0.4 ml X kg-1 X min-1; 140 +/- 25 min).,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC45) and pancuronium in anesthetized humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132566/),[ml] / [kg·min],5.2,46796,DB01339,Vecuronium
,6132566,elimination half-life,Vecuronium had a more rapid clearance (5.2 +/- 0.7 ml X kg-1 X min-1; mean +/- SD) and a shorter elimination half-life (71 +/- 20 min) as compared with pancuronium (1.8 +/- 0.4 ml X kg-1 X min-1; 140 +/- 25 min).,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC45) and pancuronium in anesthetized humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132566/),min,71,46797,DB01339,Vecuronium
,6132566,elimination half-life,Vecuronium had a more rapid clearance (5.2 +/- 0.7 ml X kg-1 X min-1; mean +/- SD) and a shorter elimination half-life (71 +/- 20 min) as compared with pancuronium (1.8 +/- 0.4 ml X kg-1 X min-1; 140 +/- 25 min).,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC45) and pancuronium in anesthetized humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132566/),[ml] / [kg·min],1.8,46798,DB01339,Vecuronium
,6132566,elimination half-life,Vecuronium had a more rapid clearance (5.2 +/- 0.7 ml X kg-1 X min-1; mean +/- SD) and a shorter elimination half-life (71 +/- 20 min) as compared with pancuronium (1.8 +/- 0.4 ml X kg-1 X min-1; 140 +/- 25 min).,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC45) and pancuronium in anesthetized humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132566/),min,140,46799,DB01339,Vecuronium
,2869721,plasma clearance rate,Vecuronium was removed faster from the plasma than pancuronium; this was reflected in a significantly larger plasma clearance rate for vecuronium (4 ml X min-1 X kg-1 vs 1.1 ml X min-1 X kg-1 for pancuronium).,Comparative pharmacokinetics and dynamics of vecuronium and pancuronium in anesthetized patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2869721/),[ml] / [kg·min],4,54165,DB01339,Vecuronium
,2869721,plasma clearance rate,Vecuronium was removed faster from the plasma than pancuronium; this was reflected in a significantly larger plasma clearance rate for vecuronium (4 ml X min-1 X kg-1 vs 1.1 ml X min-1 X kg-1 for pancuronium).,Comparative pharmacokinetics and dynamics of vecuronium and pancuronium in anesthetized patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2869721/),[ml] / [kg·min],1.1,54166,DB01339,Vecuronium
,2869721,effective plasma concentrations at 50% recovery of the twitch height,The effective plasma concentrations at 50% recovery of the twitch height were 0.11 +/- 0.02 (vecuronium) and 0.2 +/- 0.03 microgram/ml (pancuronium).,Comparative pharmacokinetics and dynamics of vecuronium and pancuronium in anesthetized patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2869721/),[μg] / [ml],0.11,54167,DB01339,Vecuronium
,2869721,effective plasma concentrations at 50% recovery of the twitch height,The effective plasma concentrations at 50% recovery of the twitch height were 0.11 +/- 0.02 (vecuronium) and 0.2 +/- 0.03 microgram/ml (pancuronium).,Comparative pharmacokinetics and dynamics of vecuronium and pancuronium in anesthetized patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2869721/),[μg] / [ml],0.2,54168,DB01339,Vecuronium
,1353252,plasma clearance,"In the patients without prolonged neuromuscular blockade, the mean (+/- SD) plasma clearance, elimination half-life, and volume of distribution of vecuronium were 2.5 +/- 1.0 ml per kilogram of body weight per minute, 299 +/- 154 minutes, and 1.1 +/- 0.6 liters per kilogram, respectively.",Persistent paralysis in critically ill patients after long-term administration of vecuronium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1353252/),[ml] / [kg],2.5,57259,DB01339,Vecuronium
,1353252,elimination half-life,"In the patients without prolonged neuromuscular blockade, the mean (+/- SD) plasma clearance, elimination half-life, and volume of distribution of vecuronium were 2.5 +/- 1.0 ml per kilogram of body weight per minute, 299 +/- 154 minutes, and 1.1 +/- 0.6 liters per kilogram, respectively.",Persistent paralysis in critically ill patients after long-term administration of vecuronium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1353252/),min,299,57260,DB01339,Vecuronium
,1353252,volume of distribution,"In the patients without prolonged neuromuscular blockade, the mean (+/- SD) plasma clearance, elimination half-life, and volume of distribution of vecuronium were 2.5 +/- 1.0 ml per kilogram of body weight per minute, 299 +/- 154 minutes, and 1.1 +/- 0.6 liters per kilogram, respectively.",Persistent paralysis in critically ill patients after long-term administration of vecuronium. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1353252/),[l] / [kg],1.1,57261,DB01339,Vecuronium
,2877876,elimination half-life,The elimination half-life was 50.7 +/- 20.3 min in normal patients and 67.826.3 min in anephric patients.,Pharmacology of vecuronium in patients with end-stage renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877876/),min,50.7,63663,DB01339,Vecuronium
,2877876,elimination half-life,The elimination half-life was 50.7 +/- 20.3 min in normal patients and 67.826.3 min in anephric patients.,Pharmacology of vecuronium in patients with end-stage renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877876/),min,67.826.3,63664,DB01339,Vecuronium
,2877876,plasma clearance,The plasma clearance was 3.6 +/- 1.5 ml min-1 for normal patients and 4.5 +/- 2.6 ml min-1 kg-1 for anephric patients.,Pharmacology of vecuronium in patients with end-stage renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877876/),[ml] / [min],3.6,63665,DB01339,Vecuronium
,2877876,plasma clearance,The plasma clearance was 3.6 +/- 1.5 ml min-1 for normal patients and 4.5 +/- 2.6 ml min-1 kg-1 for anephric patients.,Pharmacology of vecuronium in patients with end-stage renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877876/),[ml] / [kg·min],4.5,63666,DB01339,Vecuronium
,2877876,duration of action,"The duration of action in normal patients (25.3 +/- 9.8 min) was comparable to the duration of action in patients with renal failure (32.8 +/- 10.7 min), but the recovery index was prolonged (+45%, P less than 0.05) in anephric patients.",Pharmacology of vecuronium in patients with end-stage renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877876/),min,25.3,63667,DB01339,Vecuronium
,2877876,duration of action,"The duration of action in normal patients (25.3 +/- 9.8 min) was comparable to the duration of action in patients with renal failure (32.8 +/- 10.7 min), but the recovery index was prolonged (+45%, P less than 0.05) in anephric patients.",Pharmacology of vecuronium in patients with end-stage renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877876/),min,32.8,63668,DB01339,Vecuronium
,7784724,FiO2,"Anesthesia was induced with propofol (2 mg/kg), sufentanil (0.5 micrograms/kg), and vecuronium (0.08 mg/kg) and continued as total intravenous anesthesia with propofol (8 mg/kg/h) and oxygen in air (FiO2 = 0.33).",The technique of endobronchial lidocaine administration does not influence plasma concentration profiles and pharmacokinetic parameters in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7784724/),,0.,78336,DB01339,Vecuronium
,7784724,maximal mean plasma concentrations,Asorption of lidocaine in groups 1-3 resulted in maximal mean plasma concentrations ranging from 0.78 to 0.85 micrograms/ml after 16.9 to 22.4 min.,The technique of endobronchial lidocaine administration does not influence plasma concentration profiles and pharmacokinetic parameters in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7784724/),[μg] / [ml],0.78 to 0.85,78337,DB01339,Vecuronium
,2889555,steady-state volume,"For the halothane group the steady-state volume was 0.21 (+/- 0.04) L/kg, the clearance was 2.9 (+/- 0.1) ml/min/kg, and the elimination half-life was 100 (+/- 36) minutes; for the fentanyl group these were 0.20 (+/- 0.08) L/kg, 3.2 (+/- 0.1) ml/min/kg, and 84 (+/- 43) minutes, respectively.",Pharmacokinetics and pharmacodynamics of vecuronium administered by bolus and infusion during halothane or balanced anesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889555/),[l] / [kg],0.21,79728,DB01339,Vecuronium
,2889555,clearance,"For the halothane group the steady-state volume was 0.21 (+/- 0.04) L/kg, the clearance was 2.9 (+/- 0.1) ml/min/kg, and the elimination half-life was 100 (+/- 36) minutes; for the fentanyl group these were 0.20 (+/- 0.08) L/kg, 3.2 (+/- 0.1) ml/min/kg, and 84 (+/- 43) minutes, respectively.",Pharmacokinetics and pharmacodynamics of vecuronium administered by bolus and infusion during halothane or balanced anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889555/),[ml] / [kg·min],2.9,79729,DB01339,Vecuronium
,2889555,elimination half-life,"For the halothane group the steady-state volume was 0.21 (+/- 0.04) L/kg, the clearance was 2.9 (+/- 0.1) ml/min/kg, and the elimination half-life was 100 (+/- 36) minutes; for the fentanyl group these were 0.20 (+/- 0.08) L/kg, 3.2 (+/- 0.1) ml/min/kg, and 84 (+/- 43) minutes, respectively.",Pharmacokinetics and pharmacodynamics of vecuronium administered by bolus and infusion during halothane or balanced anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889555/),min,100,79730,DB01339,Vecuronium
,2889555,elimination half-life,"For the halothane group the steady-state volume was 0.21 (+/- 0.04) L/kg, the clearance was 2.9 (+/- 0.1) ml/min/kg, and the elimination half-life was 100 (+/- 36) minutes; for the fentanyl group these were 0.20 (+/- 0.08) L/kg, 3.2 (+/- 0.1) ml/min/kg, and 84 (+/- 43) minutes, respectively.",Pharmacokinetics and pharmacodynamics of vecuronium administered by bolus and infusion during halothane or balanced anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889555/),[l] / [kg],0.20,79731,DB01339,Vecuronium
,2889555,elimination half-life,"For the halothane group the steady-state volume was 0.21 (+/- 0.04) L/kg, the clearance was 2.9 (+/- 0.1) ml/min/kg, and the elimination half-life was 100 (+/- 36) minutes; for the fentanyl group these were 0.20 (+/- 0.08) L/kg, 3.2 (+/- 0.1) ml/min/kg, and 84 (+/- 43) minutes, respectively.",Pharmacokinetics and pharmacodynamics of vecuronium administered by bolus and infusion during halothane or balanced anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889555/),[ml] / [kg·min],3.2,79732,DB01339,Vecuronium
,2889555,elimination half-life,"For the halothane group the steady-state volume was 0.21 (+/- 0.04) L/kg, the clearance was 2.9 (+/- 0.1) ml/min/kg, and the elimination half-life was 100 (+/- 36) minutes; for the fentanyl group these were 0.20 (+/- 0.08) L/kg, 3.2 (+/- 0.1) ml/min/kg, and 84 (+/- 43) minutes, respectively.",Pharmacokinetics and pharmacodynamics of vecuronium administered by bolus and infusion during halothane or balanced anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889555/),min,84,79733,DB01339,Vecuronium
,2889555,Plasma concentrations,Plasma concentrations associated with 50% blockade averaged 0.2 microgram/ml for both groups.,Pharmacokinetics and pharmacodynamics of vecuronium administered by bolus and infusion during halothane or balanced anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889555/),[μg] / [ml],0.2,79734,DB01339,Vecuronium
,11132740,Cpss,"In the pre-CPB phase Cpss fell into two groups (mean +/- SD: 330 +/- 42 ng x ml(-1); 127 +/- 27 ng x ml(-1); P < 0.001); similarly the clearances showed a bimodal distribution (mean +/- SD: 5.08 +/- 0.94; 11.51 +/- 0.2 ml x min(-1) x kg(-1) P < 0.001), although in different patients.",Vecuronium pharmacokinetics and pharmacodynamics during hypothermic cardiopulmonary bypass in infants and children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11132740/),[ng] / [ml],330,82714,DB01339,Vecuronium
,11132740,Cpss,"In the pre-CPB phase Cpss fell into two groups (mean +/- SD: 330 +/- 42 ng x ml(-1); 127 +/- 27 ng x ml(-1); P < 0.001); similarly the clearances showed a bimodal distribution (mean +/- SD: 5.08 +/- 0.94; 11.51 +/- 0.2 ml x min(-1) x kg(-1) P < 0.001), although in different patients.",Vecuronium pharmacokinetics and pharmacodynamics during hypothermic cardiopulmonary bypass in infants and children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11132740/),[ng] / [ml],127,82715,DB01339,Vecuronium
,11132740,clearances,"In the pre-CPB phase Cpss fell into two groups (mean +/- SD: 330 +/- 42 ng x ml(-1); 127 +/- 27 ng x ml(-1); P < 0.001); similarly the clearances showed a bimodal distribution (mean +/- SD: 5.08 +/- 0.94; 11.51 +/- 0.2 ml x min(-1) x kg(-1) P < 0.001), although in different patients.",Vecuronium pharmacokinetics and pharmacodynamics during hypothermic cardiopulmonary bypass in infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11132740/),[ml] / [kg·min],5.08,82716,DB01339,Vecuronium
,11132740,clearances,"In the pre-CPB phase Cpss fell into two groups (mean +/- SD: 330 +/- 42 ng x ml(-1); 127 +/- 27 ng x ml(-1); P < 0.001); similarly the clearances showed a bimodal distribution (mean +/- SD: 5.08 +/- 0.94; 11.51 +/- 0.2 ml x min(-1) x kg(-1) P < 0.001), although in different patients.",Vecuronium pharmacokinetics and pharmacodynamics during hypothermic cardiopulmonary bypass in infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11132740/),[ml] / [kg·min],11.51,82717,DB01339,Vecuronium
,16169890,Apparent systemic clearances,"Apparent systemic clearances in the dissection, anhepatic and reperfusion phases were 1.89 (sd 0.48) litre min(-1), 1.08 (0.25) litre min(-1) and 1.53 (0.51) litre min(-1), respectively.",Changes in apparent systemic clearance of propofol during transplantation of living related donor liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16169890/),[l] / [min],1.89,85040,DB01339,Vecuronium
,16169890,Apparent systemic clearances,"Apparent systemic clearances in the dissection, anhepatic and reperfusion phases were 1.89 (sd 0.48) litre min(-1), 1.08 (0.25) litre min(-1) and 1.53 (0.51) litre min(-1), respectively.",Changes in apparent systemic clearance of propofol during transplantation of living related donor liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16169890/),[l] / [min],1.08,85041,DB01339,Vecuronium
,16169890,Apparent systemic clearances,"Apparent systemic clearances in the dissection, anhepatic and reperfusion phases were 1.89 (sd 0.48) litre min(-1), 1.08 (0.25) litre min(-1) and 1.53 (0.51) litre min(-1), respectively.",Changes in apparent systemic clearance of propofol during transplantation of living related donor liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16169890/),[l] / [min],1.53,85042,DB01339,Vecuronium
,16169890,intestinal extraction ratio,The intestinal extraction ratio calculated from the concentration in the radial artery and portal vein was 0.24 (0.12).,Changes in apparent systemic clearance of propofol during transplantation of living related donor liver. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16169890/),,0.24,85043,DB01339,Vecuronium
,9646009,concentration ratio (UV/MV),The umbilical/maternal vein concentration ratio (UV/MV) of nondepolarising neuromuscular relaxants varies from 7 to 26% and clinical doses of these drugs may induce partial residual curarisation in neonates.,Clinical pharmacokinetics of neuromuscular relaxants in pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646009/),%,7 to 26,106950,DB01339,Vecuronium
,15505447,recovery time,The median recovery time for train-of-four for cisatracurium (30 min) was less than that for vecuronium (180 min) (P < 0.05).,Comparison of cisatracurium and vecuronium by infusion in neonates and small infants after congenital heart surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15505447/),min,30,108572,DB01339,Vecuronium
,15505447,recovery time,The median recovery time for train-of-four for cisatracurium (30 min) was less than that for vecuronium (180 min) (P < 0.05).,Comparison of cisatracurium and vecuronium by infusion in neonates and small infants after congenital heart surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15505447/),min,180,108573,DB01339,Vecuronium
,2922980,sedation score,During infusion the sedation score decreased from 3.8 after ICU arrival to 2.2 at 8 a.m. of the first postoperative day.,Continuous infusion of midazolam during anaesthesia and postoperative sedation after maxillofacial surgery. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2922980/),,3.8,111355,DB01339,Vecuronium
,2922980,sedation score,During infusion the sedation score decreased from 3.8 after ICU arrival to 2.2 at 8 a.m. of the first postoperative day.,Continuous infusion of midazolam during anaesthesia and postoperative sedation after maxillofacial surgery. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2922980/),,2.2,111356,DB01339,Vecuronium
,2922980,T1/2 beta,T1/2 beta of MDZ after cessation was 125 min (range 90-320) and its total body clearance was 10.5 ml/kg/min (s.d. = 3.1).,Continuous infusion of midazolam during anaesthesia and postoperative sedation after maxillofacial surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2922980/),min,125,111357,DB01339,Vecuronium
,2922980,total body clearance,T1/2 beta of MDZ after cessation was 125 min (range 90-320) and its total body clearance was 10.5 ml/kg/min (s.d. = 3.1).,Continuous infusion of midazolam during anaesthesia and postoperative sedation after maxillofacial surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2922980/),[ml] / [kg·min],10.5,111358,DB01339,Vecuronium
,1348166,Times to 50% recovery of twitch,Times to 50% recovery of twitch were longer in the obese than in the control patients (75 +/- 8 versus 46 +/- 8 min) as were 5%-25% recovery times (14.9 +/- 4.0 versus 10.0 +/- 1.7 min) and 25%-75% recovery times (38.4 +/- 13.8 versus 16.7 +/- 10.3 min).,Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),min,75,111543,DB01339,Vecuronium
,1348166,Times to 50% recovery of twitch,Times to 50% recovery of twitch were longer in the obese than in the control patients (75 +/- 8 versus 46 +/- 8 min) as were 5%-25% recovery times (14.9 +/- 4.0 versus 10.0 +/- 1.7 min) and 25%-75% recovery times (38.4 +/- 13.8 versus 16.7 +/- 10.3 min).,Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),min,46,111544,DB01339,Vecuronium
,1348166,5%-25% recovery times,Times to 50% recovery of twitch were longer in the obese than in the control patients (75 +/- 8 versus 46 +/- 8 min) as were 5%-25% recovery times (14.9 +/- 4.0 versus 10.0 +/- 1.7 min) and 25%-75% recovery times (38.4 +/- 13.8 versus 16.7 +/- 10.3 min).,Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),min,14.9,111545,DB01339,Vecuronium
,1348166,5%-25% recovery times,Times to 50% recovery of twitch were longer in the obese than in the control patients (75 +/- 8 versus 46 +/- 8 min) as were 5%-25% recovery times (14.9 +/- 4.0 versus 10.0 +/- 1.7 min) and 25%-75% recovery times (38.4 +/- 13.8 versus 16.7 +/- 10.3 min).,Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),min,10.0,111546,DB01339,Vecuronium
,1348166,25%-75% recovery times,Times to 50% recovery of twitch were longer in the obese than in the control patients (75 +/- 8 versus 46 +/- 8 min) as were 5%-25% recovery times (14.9 +/- 4.0 versus 10.0 +/- 1.7 min) and 25%-75% recovery times (38.4 +/- 13.8 versus 16.7 +/- 10.3 min).,Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),min,38.4,111547,DB01339,Vecuronium
,1348166,25%-75% recovery times,Times to 50% recovery of twitch were longer in the obese than in the control patients (75 +/- 8 versus 46 +/- 8 min) as were 5%-25% recovery times (14.9 +/- 4.0 versus 10.0 +/- 1.7 min) and 25%-75% recovery times (38.4 +/- 13.8 versus 16.7 +/- 10.3 min).,Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),min,16.7,111548,DB01339,Vecuronium
,1348166,total volume of distribution,"When the data were calculated on the basis of ideal body weight (IBW) for obese and control patients, total volume of distribution (791 +/- 303 versus 919 +/- 360 mL/kg IBW), plasma clearance (4.65 +/- 0.89 versus 5.02 +/- 1.13 mL.min-1.kg IBW-1), and elimination half-life (119 +/- 43 versus 133 +/- 57 min) were not different between groups.",Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),[ml] / [kg],791,111549,DB01339,Vecuronium
,1348166,total volume of distribution,"When the data were calculated on the basis of ideal body weight (IBW) for obese and control patients, total volume of distribution (791 +/- 303 versus 919 +/- 360 mL/kg IBW), plasma clearance (4.65 +/- 0.89 versus 5.02 +/- 1.13 mL.min-1.kg IBW-1), and elimination half-life (119 +/- 43 versus 133 +/- 57 min) were not different between groups.",Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),[ml] / [kg],919,111550,DB01339,Vecuronium
,1348166,plasma clearance,"When the data were calculated on the basis of ideal body weight (IBW) for obese and control patients, total volume of distribution (791 +/- 303 versus 919 +/- 360 mL/kg IBW), plasma clearance (4.65 +/- 0.89 versus 5.02 +/- 1.13 mL.min-1.kg IBW-1), and elimination half-life (119 +/- 43 versus 133 +/- 57 min) were not different between groups.",Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),[kg·ml] / [ibw·min],4.65,111551,DB01339,Vecuronium
,1348166,plasma clearance,"When the data were calculated on the basis of ideal body weight (IBW) for obese and control patients, total volume of distribution (791 +/- 303 versus 919 +/- 360 mL/kg IBW), plasma clearance (4.65 +/- 0.89 versus 5.02 +/- 1.13 mL.min-1.kg IBW-1), and elimination half-life (119 +/- 43 versus 133 +/- 57 min) were not different between groups.",Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),[kg·ml] / [ibw·min],5.02,111552,DB01339,Vecuronium
,1348166,elimination half-life,"When the data were calculated on the basis of ideal body weight (IBW) for obese and control patients, total volume of distribution (791 +/- 303 versus 919 +/- 360 mL/kg IBW), plasma clearance (4.65 +/- 0.89 versus 5.02 +/- 1.13 mL.min-1.kg IBW-1), and elimination half-life (119 +/- 43 versus 133 +/- 57 min) were not different between groups.",Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),min,119,111553,DB01339,Vecuronium
,1348166,elimination half-life,"When the data were calculated on the basis of ideal body weight (IBW) for obese and control patients, total volume of distribution (791 +/- 303 versus 919 +/- 360 mL/kg IBW), plasma clearance (4.65 +/- 0.89 versus 5.02 +/- 1.13 mL.min-1.kg IBW-1), and elimination half-life (119 +/- 43 versus 133 +/- 57 min) were not different between groups.",Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),min,133,111554,DB01339,Vecuronium
,15681947,renal extraction ratio,The renal extraction ratio of propofol was 0.58 +/- 0.15 (mean +/- SD).,Human kidneys play an important role in the elimination of propofol. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15681947/),,0.58,112897,DB01339,Vecuronium
,15681947,renal clearance,"The renal clearance of propofol was 0.41 +/- 0.15 l/min (mean +/- SD), or 27 +/- 9.9% (mean +/- SD) of total body clearance.",Human kidneys play an important role in the elimination of propofol. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15681947/),[l] / [min],0.41,112898,DB01339,Vecuronium
,15681947,renal clearance,"The renal clearance of propofol was 0.41 +/- 0.15 l/min (mean +/- SD), or 27 +/- 9.9% (mean +/- SD) of total body clearance.",Human kidneys play an important role in the elimination of propofol. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15681947/),%,27,112899,DB01339,Vecuronium
,2861839,half-lives,"Concentrations decreased bi-exponentially with half-lives of 4.6 and 31 min, respectively.",Disposition of vecuronium bromide in the cat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2861839/),min,4.6,113260,DB01339,Vecuronium
,2861839,half-lives,"Concentrations decreased bi-exponentially with half-lives of 4.6 and 31 min, respectively.",Disposition of vecuronium bromide in the cat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2861839/),min,31,113261,DB01339,Vecuronium
,2861839,steady state volume of distribution,The steady state volume of distribution was 0.23 litre kg-1 and the clearance 11 ml min-1 kg-1.,Disposition of vecuronium bromide in the cat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2861839/),[l] / [kg],0.23,113262,DB01339,Vecuronium
,2861839,clearance,The steady state volume of distribution was 0.23 litre kg-1 and the clearance 11 ml min-1 kg-1.,Disposition of vecuronium bromide in the cat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2861839/),[ml] / [kg·min],11,113263,DB01339,Vecuronium
,24067332,distributional clearance at the terminal phase,"Burn patients showed enhanced distributional clearance at the terminal phase (0.12 vs 0.095 litre min(-1), P<0.0001), which yielded shorter elimination half-life for vecuronium (5.5 vs 6.6 h, P<0.001).",Vecuronium pharmacokinetics in patients with major burns. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24067332/),[l] / [min],0.12,120377,DB01339,Vecuronium
,24067332,distributional clearance at the terminal phase,"Burn patients showed enhanced distributional clearance at the terminal phase (0.12 vs 0.095 litre min(-1), P<0.0001), which yielded shorter elimination half-life for vecuronium (5.5 vs 6.6 h, P<0.001).",Vecuronium pharmacokinetics in patients with major burns. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24067332/),[l] / [min],0.095,120378,DB01339,Vecuronium
,24067332,elimination half-life,"Burn patients showed enhanced distributional clearance at the terminal phase (0.12 vs 0.095 litre min(-1), P<0.0001), which yielded shorter elimination half-life for vecuronium (5.5 vs 6.6 h, P<0.001).",Vecuronium pharmacokinetics in patients with major burns. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24067332/),h,5.5,120379,DB01339,Vecuronium
,24067332,elimination half-life,"Burn patients showed enhanced distributional clearance at the terminal phase (0.12 vs 0.095 litre min(-1), P<0.0001), which yielded shorter elimination half-life for vecuronium (5.5 vs 6.6 h, P<0.001).",Vecuronium pharmacokinetics in patients with major burns. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24067332/),h,6.6,120380,DB01339,Vecuronium
,10638903,rate constant,"Decreasing core temperature over 38.0-34.0 degrees C decreases the plasma clearance of vecuronium (11.3% per degrees C), decreases the rate constant for drug equilibration between plasma and effect site (0.023 min(-1) per degrees C), and increases the slope of the concentration-response relationship (0.43 per degrees C).",Temperature-dependent pharmacokinetics and pharmacodynamics of vecuronium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10638903/),1/[c·degrees·min],0.023,128475,DB01339,Vecuronium
,2859815,plasma clearance,Vecuronium plasma clearance was reduced significantly (P less than 0.01) from 4.26 +/- 1.38 ml X min-1 X kg-1 in the controls to 2.73 +/- 1.19 ml X min-1 X kg-1 in the patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859815/),[ml] / [kg·min],4.26,130536,DB01339,Vecuronium
,2859815,plasma clearance,Vecuronium plasma clearance was reduced significantly (P less than 0.01) from 4.26 +/- 1.38 ml X min-1 X kg-1 in the controls to 2.73 +/- 1.19 ml X min-1 X kg-1 in the patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859815/),[ml] / [kg·min],2.73,130537,DB01339,Vecuronium
,2859815,elimination half-life,The elimination half-life was 58 +/- 19 min in the controls and was prolonged significantly to 84 +/- 23 min (P less than 0.01) in the patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859815/),min,58,130538,DB01339,Vecuronium
,2859815,elimination half-life,The elimination half-life was 58 +/- 19 min in the controls and was prolonged significantly to 84 +/- 23 min (P less than 0.01) in the patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859815/),min,84,130539,DB01339,Vecuronium
,2859815,total apparent volume of distribution,The total apparent volume of distribution was unchanged in patients with cirrhosis (0.253 +/- 0.086 1 X kg-1 vs. 0.246 +/- 0.092 1 X kg-1 in the controls).,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) in patients with cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859815/),[1] / [kg],0.253,130540,DB01339,Vecuronium
,2859815,total apparent volume of distribution,The total apparent volume of distribution was unchanged in patients with cirrhosis (0.253 +/- 0.086 1 X kg-1 vs. 0.246 +/- 0.092 1 X kg-1 in the controls).,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) in patients with cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859815/),[1] / [kg],0.246,130541,DB01339,Vecuronium
,2859815,duration of effect,Cirrhosis caused a prolongation of the neuromuscular blockade induced by vecuronium: the duration of effect from injection to 50% recovery of the twitch height was prolonged by 100% (P less than 0.01) from 62 +/- 16 min in the controls to 130 +/- 52 min in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859815/),min,62,130542,DB01339,Vecuronium
,2859815,duration of effect,Cirrhosis caused a prolongation of the neuromuscular blockade induced by vecuronium: the duration of effect from injection to 50% recovery of the twitch height was prolonged by 100% (P less than 0.01) from 62 +/- 16 min in the controls to 130 +/- 52 min in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859815/),min,130,130543,DB01339,Vecuronium
,2859815,recovery rate (TH 25-75),The recovery rate (TH 25-75) also was prolonged (P less than 0.05) from 21 +/- 7 min in the controls to 44 +/- 18 min in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859815/),min,21,130544,DB01339,Vecuronium
,2859815,recovery rate (TH 25-75),The recovery rate (TH 25-75) also was prolonged (P less than 0.05) from 21 +/- 7 min in the controls to 44 +/- 18 min in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859815/),min,44,130545,DB01339,Vecuronium
,7925211,volume of distribution at steady state,"The pharmacokinetic parameters (volume of distribution at steady state, 309 +/- 80 ml kg-1, plasma clearance 4.5 +/- 1.96 ml kg-1 min-1, and elimination half-life 107 +/- 37 min) were similar to those previously reported after a large single bolus.",Pharmacodynamics and pharmacokinetics of rocuronium following continuous infusion in patients during intravenous anaesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7925211/),[ml] / [kg],309,132043,DB01339,Vecuronium
,7925211,plasma clearance,"The pharmacokinetic parameters (volume of distribution at steady state, 309 +/- 80 ml kg-1, plasma clearance 4.5 +/- 1.96 ml kg-1 min-1, and elimination half-life 107 +/- 37 min) were similar to those previously reported after a large single bolus.",Pharmacodynamics and pharmacokinetics of rocuronium following continuous infusion in patients during intravenous anaesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7925211/),[ml] / [kg·min],4.5,132044,DB01339,Vecuronium
,7925211,elimination half-life,"The pharmacokinetic parameters (volume of distribution at steady state, 309 +/- 80 ml kg-1, plasma clearance 4.5 +/- 1.96 ml kg-1 min-1, and elimination half-life 107 +/- 37 min) were similar to those previously reported after a large single bolus.",Pharmacodynamics and pharmacokinetics of rocuronium following continuous infusion in patients during intravenous anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7925211/),min,107,132045,DB01339,Vecuronium
,9620528,end,General anesthesia was induced with thiopental 4-6 mg/kg and fentanyl 2-4 microg/kg and was maintained with 60% nitrous oxide in oxygen and an end-tidal concentration of 1.5%-2% enflurane.,The pharmacokinetics of vecuronium in male and female patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620528/),,1,134931,DB01339,Vecuronium
,9620528,volume of the central compartment,"The volume of the central compartment and the volume of distribution at steady state were 39.6 +/- 8.6 and 164.8 +/- 29.3 mL/kg, respectively, in women.",The pharmacokinetics of vecuronium in male and female patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620528/),[ml] / [kg],39.6,134932,DB01339,Vecuronium
,9620528,volume of distribution at steady state,"The volume of the central compartment and the volume of distribution at steady state were 39.6 +/- 8.6 and 164.8 +/- 29.3 mL/kg, respectively, in women.",The pharmacokinetics of vecuronium in male and female patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620528/),[ml] / [kg],164.8,134933,DB01339,Vecuronium
,2889403,initial rate,"Thirty healthy surgical patients were given an initial 0.1 mg/kg bolus of vecuronium, followed by an infusion of vecuronium at an initial rate of 1.0 microgram .",Continuous infusion of vecuronium: the effect of anesthetic agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),,1,138618,DB01339,Vecuronium
,2889403,infusion rates,"Vecuronium infusion rates (mean +/- SD) were similar for patients given enflurane (0.28 +/- 0.13 microgram . kg-1 . min-1) and isoflurane (0.30 +/- 0.13 microgram . kg-1 . min-1), but significantly higher in patients given fentanyl (0.92 +/- 0.37 microgram . kg-1 . min-1).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[μg] / [kg·min],0.28,138619,DB01339,Vecuronium
,2889403,infusion rates,"Vecuronium infusion rates (mean +/- SD) were similar for patients given enflurane (0.28 +/- 0.13 microgram . kg-1 . min-1) and isoflurane (0.30 +/- 0.13 microgram . kg-1 . min-1), but significantly higher in patients given fentanyl (0.92 +/- 0.37 microgram . kg-1 . min-1).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[μg] / [kg·min],0.30,138620,DB01339,Vecuronium
,2889403,infusion rates,"Vecuronium infusion rates (mean +/- SD) were similar for patients given enflurane (0.28 +/- 0.13 microgram . kg-1 . min-1) and isoflurane (0.30 +/- 0.13 microgram . kg-1 . min-1), but significantly higher in patients given fentanyl (0.92 +/- 0.37 microgram . kg-1 . min-1).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[μg] / [kg·min],0.92,138621,DB01339,Vecuronium
,2889403,Css90,"Values for Css90 in the patients receiving enflurane and isoflurane were similar (71 +/- 34 and 72 +/- 44 ng/ml, respectively), but significantly higher in those receiving fentanyl (165 +/- 48 ng/ml).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[ng] / [ml],71,138622,DB01339,Vecuronium
,2889403,Css90,"Values for Css90 in the patients receiving enflurane and isoflurane were similar (71 +/- 34 and 72 +/- 44 ng/ml, respectively), but significantly higher in those receiving fentanyl (165 +/- 48 ng/ml).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[ng] / [ml],72,138623,DB01339,Vecuronium
,2889403,Css90,"Values for Css90 in the patients receiving enflurane and isoflurane were similar (71 +/- 34 and 72 +/- 44 ng/ml, respectively), but significantly higher in those receiving fentanyl (165 +/- 48 ng/ml).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[ng] / [ml],165,138624,DB01339,Vecuronium
,2889403,Total plasma clearance,"Total plasma clearance was similar during enflurane, isoflurane, and fentanyl anesthesia (4.4 +/- 2.6, 4.6 +/- 1.2, and 5.6 +/- 1.9 ml X kg-1 min-1, respectively).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[ml] / [kg·min],4.4,138625,DB01339,Vecuronium
,2889403,Total plasma clearance,"Total plasma clearance was similar during enflurane, isoflurane, and fentanyl anesthesia (4.4 +/- 2.6, 4.6 +/- 1.2, and 5.6 +/- 1.9 ml X kg-1 min-1, respectively).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[ml] / [kg·min],4.6,138626,DB01339,Vecuronium
,2889403,Total plasma clearance,"Total plasma clearance was similar during enflurane, isoflurane, and fentanyl anesthesia (4.4 +/- 2.6, 4.6 +/- 1.2, and 5.6 +/- 1.9 ml X kg-1 min-1, respectively).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[ml] / [kg·min],5.6,138627,DB01339,Vecuronium
,6115592,plasma half-lives,"The plasma half-lives varied from 3 to 15 min, and are about one third of that of the structurally-related compound pancuronium.",Pharmacokinetics and pharmacodynamics of the muscle relaxant drug Org NC-45 and each of its hydroxy metabolites in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6115592/),min,3 to 15,139297,DB01339,Vecuronium
,6115592,Renal excretion,Renal excretion was of the order 5-20% and the biliary excretion 7-20% 6 h after administration of each of the 4 compounds.,Pharmacokinetics and pharmacodynamics of the muscle relaxant drug Org NC-45 and each of its hydroxy metabolites in dogs. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6115592/),%,5-20,139298,DB01339,Vecuronium
,6115592,biliary excretion,Renal excretion was of the order 5-20% and the biliary excretion 7-20% 6 h after administration of each of the 4 compounds.,Pharmacokinetics and pharmacodynamics of the muscle relaxant drug Org NC-45 and each of its hydroxy metabolites in dogs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6115592/),%,7-20,139299,DB01339,Vecuronium
,1687880,low detection limit,The low detection limit of this method in the patient was 3 ng/mL.,Determination of vecuronium in blood by HPLC with UV and electrochemical detection: a pilot study in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687880/),[ng] / [ml],3,142308,DB01339,Vecuronium
,7913801,recovery time,"Atracurium's recovery time increased 2.4 +/- 2.2 min (mean +/- SD) with the larger dose, less than the increase with vecuronium (8.2 +/- 3.8 min).",Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913801/),min,2.4,144052,DB01339,Vecuronium
,7913801,recovery time,"Atracurium's recovery time increased 2.4 +/- 2.2 min (mean +/- SD) with the larger dose, less than the increase with vecuronium (8.2 +/- 3.8 min).",Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913801/),min,8.2,144053,DB01339,Vecuronium
,7913801,recovery phase half-life,Atracurium's recovery phase half-life was 14.6 +/- 1.7 and 20.1 +/- 2.3 min with the small and large doses (P < 0.05); vecuronium's recovery phase half-life increased similarly from 13.5 +/- 2.3 to 18.5 +/- 5.0 min (P < 0.05).,Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913801/),min,14.6,144054,DB01339,Vecuronium
,7913801,recovery phase half-life,Atracurium's recovery phase half-life was 14.6 +/- 1.7 and 20.1 +/- 2.3 min with the small and large doses (P < 0.05); vecuronium's recovery phase half-life increased similarly from 13.5 +/- 2.3 to 18.5 +/- 5.0 min (P < 0.05).,Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913801/),min,20.1,144055,DB01339,Vecuronium
,7913801,recovery phase half-life,Atracurium's recovery phase half-life was 14.6 +/- 1.7 and 20.1 +/- 2.3 min with the small and large doses (P < 0.05); vecuronium's recovery phase half-life increased similarly from 13.5 +/- 2.3 to 18.5 +/- 5.0 min (P < 0.05).,Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913801/),min,13.5,144056,DB01339,Vecuronium
,7913801,recovery phase half-life,Atracurium's recovery phase half-life was 14.6 +/- 1.7 and 20.1 +/- 2.3 min with the small and large doses (P < 0.05); vecuronium's recovery phase half-life increased similarly from 13.5 +/- 2.3 to 18.5 +/- 5.0 min (P < 0.05).,Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913801/),min,18.5,144057,DB01339,Vecuronium
,7913801,Ce,"At 75% recovery, vecuronium's Ce decreased from 65 +/- 18 ng/ml with the small dose to 55 +/- 15 ng/ml with the large dose (P < 0.05).",Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913801/),[ng] / [ml],65,144058,DB01339,Vecuronium
,7913801,Ce,"At 75% recovery, vecuronium's Ce decreased from 65 +/- 18 ng/ml with the small dose to 55 +/- 15 ng/ml with the large dose (P < 0.05).",Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913801/),[ng] / [ml],55,144059,DB01339,Vecuronium
,7946859,infusion requirements,"During the final 15 min of infusion, the infusion requirements were 2.5 (1.1) mg kg-1 h-1.","Pharmacodynamics and pharmacokinetics of an infusion of Org 9487, a new short-acting steroidal neuromuscular blocking agent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946859/),[mg] / [h·kg],2.5,144207,DB01339,Vecuronium
,7946859,TOF ratio,"In the five patients who were allowed to recover spontaneously, a TOF ratio of 0.7 was reached 37.9 (12.4) min after stopping the infusion of Org 9487.","Pharmacodynamics and pharmacokinetics of an infusion of Org 9487, a new short-acting steroidal neuromuscular blocking agent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946859/),,0.7,144208,DB01339,Vecuronium
,7946859,TOF ratio,"In the five patients who were allowed to recover spontaneously, a TOF ratio of 0.7 was reached 37.9 (12.4) min after stopping the infusion of Org 9487.","Pharmacodynamics and pharmacokinetics of an infusion of Org 9487, a new short-acting steroidal neuromuscular blocking agent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946859/),min,37.9,144209,DB01339,Vecuronium
,7946859,TOF ratio,"In the five patients who received neostigmine, a TOF ratio of 0.7 was reached after 14.5 (6.1) min.","Pharmacodynamics and pharmacokinetics of an infusion of Org 9487, a new short-acting steroidal neuromuscular blocking agent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946859/),,0.7,144210,DB01339,Vecuronium
,7946859,Plasma clearance,Plasma clearance was 8.5 (30%) ml kg-1 min-1.,"Pharmacodynamics and pharmacokinetics of an infusion of Org 9487, a new short-acting steroidal neuromuscular blocking agent. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946859/),[ml] / [kg·min],8.5,144211,DB01339,Vecuronium
,7946859,Volume of distribution at steady state,Volume of distribution at steady state was 293 (55%) ml kg-1.,"Pharmacodynamics and pharmacokinetics of an infusion of Org 9487, a new short-acting steroidal neuromuscular blocking agent. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946859/),[ml] / [kg],293,144212,DB01339,Vecuronium
,7946859,Terminal half-life,"Terminal half-life and mean residence time were 71.7 (34%) and 33.4 (31%) min, respectively.","Pharmacodynamics and pharmacokinetics of an infusion of Org 9487, a new short-acting steroidal neuromuscular blocking agent. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946859/),min,71.7,144213,DB01339,Vecuronium
,7946859,mean residence time,"Terminal half-life and mean residence time were 71.7 (34%) and 33.4 (31%) min, respectively.","Pharmacodynamics and pharmacokinetics of an infusion of Org 9487, a new short-acting steroidal neuromuscular blocking agent. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946859/),min,33.4,144214,DB01339,Vecuronium
,7946859,Urinary excretion,Urinary excretion of Org 9487 and its metabolites was 22% in 24 h.,"Pharmacodynamics and pharmacokinetics of an infusion of Org 9487, a new short-acting steroidal neuromuscular blocking agent. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946859/),%,22,144215,DB01339,Vecuronium
,8544280,clinical duration,"The clinical duration of vecuronium, defined as recovery to 25% of the control first twitch in the train-of-four sequence, was significantly longer in the clonidine group (51.2 +/- 7.5 minutes compared with 40.5 +/- 5.1 minutes in the control group, P < 0.01).",[The effect of clonidine on the duration of vecuronium-induced neuromuscular blockade in humans]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8544280/),min,51.2,152868,DB01339,Vecuronium
,8544280,clinical duration,"The clinical duration of vecuronium, defined as recovery to 25% of the control first twitch in the train-of-four sequence, was significantly longer in the clonidine group (51.2 +/- 7.5 minutes compared with 40.5 +/- 5.1 minutes in the control group, P < 0.01).",[The effect of clonidine on the duration of vecuronium-induced neuromuscular blockade in humans]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8544280/),min,40.5,152869,DB01339,Vecuronium
,1976829,T1/2 alpha,"With pipecuronium, following pharmacokinetic parameters were obtained; distribution half-life; T1/2 alpha = 3.9 +/- 0.7 min (mean +/- SEM), elimination half-life; T1/2 beta = 102 +/- 12 min, volume of the central compartment; V1 = 95 +/- 13 ml.kg-1, volume of distribution at steady state; Vdss = 264 +/- 41 ml.kg-1, clearance; Cl = 1.8 +/- 0.2 ml.min-1.kg-1.","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),min,3.9,158846,DB01339,Vecuronium
,1976829,T1/2 beta,"With pipecuronium, following pharmacokinetic parameters were obtained; distribution half-life; T1/2 alpha = 3.9 +/- 0.7 min (mean +/- SEM), elimination half-life; T1/2 beta = 102 +/- 12 min, volume of the central compartment; V1 = 95 +/- 13 ml.kg-1, volume of distribution at steady state; Vdss = 264 +/- 41 ml.kg-1, clearance; Cl = 1.8 +/- 0.2 ml.min-1.kg-1.","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),min,102,158847,DB01339,Vecuronium
,1976829,V1,"With pipecuronium, following pharmacokinetic parameters were obtained; distribution half-life; T1/2 alpha = 3.9 +/- 0.7 min (mean +/- SEM), elimination half-life; T1/2 beta = 102 +/- 12 min, volume of the central compartment; V1 = 95 +/- 13 ml.kg-1, volume of distribution at steady state; Vdss = 264 +/- 41 ml.kg-1, clearance; Cl = 1.8 +/- 0.2 ml.min-1.kg-1.","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg],95,158848,DB01339,Vecuronium
,1976829,Vdss,"With pipecuronium, following pharmacokinetic parameters were obtained; distribution half-life; T1/2 alpha = 3.9 +/- 0.7 min (mean +/- SEM), elimination half-life; T1/2 beta = 102 +/- 12 min, volume of the central compartment; V1 = 95 +/- 13 ml.kg-1, volume of distribution at steady state; Vdss = 264 +/- 41 ml.kg-1, clearance; Cl = 1.8 +/- 0.2 ml.min-1.kg-1.","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg],264,158849,DB01339,Vecuronium
,1976829,Cl,"With pipecuronium, following pharmacokinetic parameters were obtained; distribution half-life; T1/2 alpha = 3.9 +/- 0.7 min (mean +/- SEM), elimination half-life; T1/2 beta = 102 +/- 12 min, volume of the central compartment; V1 = 95 +/- 13 ml.kg-1, volume of distribution at steady state; Vdss = 264 +/- 41 ml.kg-1, clearance; Cl = 1.8 +/- 0.2 ml.min-1.kg-1.","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg·min],1.8,158850,DB01339,Vecuronium
,1976829,V1,V1 and Vdss of pipecuronium were significantly larger than those of pancuronium (V1; 38 +/- 12 ml.kg-1 and Vdss; 120 +/- 4 ml.kg-1) (both P less than 0.10).,"[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg],38,158851,DB01339,Vecuronium
,1976829,Vdss,V1 and Vdss of pipecuronium were significantly larger than those of pancuronium (V1; 38 +/- 12 ml.kg-1 and Vdss; 120 +/- 4 ml.kg-1) (both P less than 0.10).,"[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg],120,158852,DB01339,Vecuronium
,1976829,Cl,"Reflecting the larger central volume of pipecuronium, pipecuronium tended to have a larger clearance than that of pancuroniumu (Cl; 1.1 +/- 0.2 ml.min-1.kg-1).","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg·min],1.1,158853,DB01339,Vecuronium
,9597210,Maximum blood thiopentone concentration,"Maximum blood thiopentone concentration in the precipitate group was lower than in the control group (12.9 +/- 4.5 vs 17.0 +/- 1.6 micrograms.ml, P < 0.05), although the half-life of thiopentone in the precipitate group was longer (32.3 +/- 8.5 vs 21.7 +/- 8.2 min, P < 0.05) and the area under the time concentration curve was similar between the two groups.",Precipitate formed by thiopentone and vecuronium causes pulmonary embolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9597210/),ml·μg,12.9,161296,DB01339,Vecuronium
,9597210,Maximum blood thiopentone concentration,"Maximum blood thiopentone concentration in the precipitate group was lower than in the control group (12.9 +/- 4.5 vs 17.0 +/- 1.6 micrograms.ml, P < 0.05), although the half-life of thiopentone in the precipitate group was longer (32.3 +/- 8.5 vs 21.7 +/- 8.2 min, P < 0.05) and the area under the time concentration curve was similar between the two groups.",Precipitate formed by thiopentone and vecuronium causes pulmonary embolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9597210/),ml·μg,17.0,161297,DB01339,Vecuronium
,9597210,half-life,"Maximum blood thiopentone concentration in the precipitate group was lower than in the control group (12.9 +/- 4.5 vs 17.0 +/- 1.6 micrograms.ml, P < 0.05), although the half-life of thiopentone in the precipitate group was longer (32.3 +/- 8.5 vs 21.7 +/- 8.2 min, P < 0.05) and the area under the time concentration curve was similar between the two groups.",Precipitate formed by thiopentone and vecuronium causes pulmonary embolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9597210/),min,32.3,161298,DB01339,Vecuronium
,9597210,half-life,"Maximum blood thiopentone concentration in the precipitate group was lower than in the control group (12.9 +/- 4.5 vs 17.0 +/- 1.6 micrograms.ml, P < 0.05), although the half-life of thiopentone in the precipitate group was longer (32.3 +/- 8.5 vs 21.7 +/- 8.2 min, P < 0.05) and the area under the time concentration curve was similar between the two groups.",Precipitate formed by thiopentone and vecuronium causes pulmonary embolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9597210/),min,21.7,161299,DB01339,Vecuronium
,9597210,PaO2,"The PaO2 was lower in the precipitate group than in controls one minute after injection (431 +/- 27 vs 464 +/- 18 mmHg, P < 0.05) but not subsequently.",Precipitate formed by thiopentone and vecuronium causes pulmonary embolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9597210/),mmhg,431,161300,DB01339,Vecuronium
,9597210,PaO2,"The PaO2 was lower in the precipitate group than in controls one minute after injection (431 +/- 27 vs 464 +/- 18 mmHg, P < 0.05) but not subsequently.",Precipitate formed by thiopentone and vecuronium causes pulmonary embolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9597210/),mmhg,464,161301,DB01339,Vecuronium
,6145374,clearance,"Vecuronium had a more rapid clearance (6.4 +/- 0.4 ml X kg-1 X min-1, mean +/- SE) and a shorter elimination half-life (36 +/- 1.8 min) than pancuronium (3.0 +/- 0.1 ml X kg-1 X min-1 and 72 +/- 6 min, respectively).","Pharmacokinetics, placental transfer, and neonatal effects of vecuronium and pancuronium administered during cesarean section. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145374/),[ml] / [kg·min],6.4,178725,DB01339,Vecuronium
,6145374,elimination half-life,"Vecuronium had a more rapid clearance (6.4 +/- 0.4 ml X kg-1 X min-1, mean +/- SE) and a shorter elimination half-life (36 +/- 1.8 min) than pancuronium (3.0 +/- 0.1 ml X kg-1 X min-1 and 72 +/- 6 min, respectively).","Pharmacokinetics, placental transfer, and neonatal effects of vecuronium and pancuronium administered during cesarean section. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145374/),min,36,178726,DB01339,Vecuronium
,6145374,elimination half-life,"Vecuronium had a more rapid clearance (6.4 +/- 0.4 ml X kg-1 X min-1, mean +/- SE) and a shorter elimination half-life (36 +/- 1.8 min) than pancuronium (3.0 +/- 0.1 ml X kg-1 X min-1 and 72 +/- 6 min, respectively).","Pharmacokinetics, placental transfer, and neonatal effects of vecuronium and pancuronium administered during cesarean section. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145374/),[ml] / [kg·min],3.0,178727,DB01339,Vecuronium
,6145374,elimination half-life,"Vecuronium had a more rapid clearance (6.4 +/- 0.4 ml X kg-1 X min-1, mean +/- SE) and a shorter elimination half-life (36 +/- 1.8 min) than pancuronium (3.0 +/- 0.1 ml X kg-1 X min-1 and 72 +/- 6 min, respectively).","Pharmacokinetics, placental transfer, and neonatal effects of vecuronium and pancuronium administered during cesarean section. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145374/),min,72,178728,DB01339,Vecuronium
,8602663,recovery times to T(1),"In the carbamazepine group, the mean recovery times to T(1) 25% were shorter (28.1 +/- 3.4 vs. 47.3 +/- 5.1 min in control subjects; P=0.007), and the T(1) 25% to T(1) 75% recovery index was decreased (7.6 +/- 1.2 vs. 21.9 +/- 6.8 min in control subjects; P=0.025).",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),min,28.1,180814,DB01339,Vecuronium
,8602663,recovery times to T(1),"In the carbamazepine group, the mean recovery times to T(1) 25% were shorter (28.1 +/- 3.4 vs. 47.3 +/- 5.1 min in control subjects; P=0.007), and the T(1) 25% to T(1) 75% recovery index was decreased (7.6 +/- 1.2 vs. 21.9 +/- 6.8 min in control subjects; P=0.025).",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),min,47.3,180815,DB01339,Vecuronium
,8602663,T(1) 25% to T(1) 75% recovery index,"In the carbamazepine group, the mean recovery times to T(1) 25% were shorter (28.1 +/- 3.4 vs. 47.3 +/- 5.1 min in control subjects; P=0.007), and the T(1) 25% to T(1) 75% recovery index was decreased (7.6 +/- 1.2 vs. 21.9 +/- 6.8 min in control subjects; P=0.025).",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),min,7.6,180816,DB01339,Vecuronium
,8602663,T(1) 25% to T(1) 75% recovery index,"In the carbamazepine group, the mean recovery times to T(1) 25% were shorter (28.1 +/- 3.4 vs. 47.3 +/- 5.1 min in control subjects; P=0.007), and the T(1) 25% to T(1) 75% recovery index was decreased (7.6 +/- 1.2 vs. 21.9 +/- 6.8 min in control subjects; P=0.025).",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),min,21.9,180817,DB01339,Vecuronium
,8602663,Clearance,"Clearance was 9.0 +/- 1.2 ml x kg-1 x min-1 versus 3.8 +/- 0.3 in the control group (P=0.003), whereas no changes in volumes of distribution at steady-state were observed.",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),[ml] / [kg·min],9.0,180818,DB01339,Vecuronium
,8602663,Clearance,"Clearance was 9.0 +/- 1.2 ml x kg-1 x min-1 versus 3.8 +/- 0.3 in the control group (P=0.003), whereas no changes in volumes of distribution at steady-state were observed.",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),,3.8,180819,DB01339,Vecuronium
,8602663,mean residence time,"Therefore, the mean residence time was halved (17.8 +/- 2.5 vs. 31.9 +/- 2.5 min in control subjects; P=0.001).",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),min,17.8,180820,DB01339,Vecuronium
,8602663,mean residence time,"Therefore, the mean residence time was halved (17.8 +/- 2.5 vs. 31.9 +/- 2.5 min in control subjects; P=0.001).",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),min,31.9,180821,DB01339,Vecuronium
,3063133,respiratory rate,"Ventilation was performed mechanically during the entire operative period (N2O/O2 - FiO2:0.33, tidal volume 10 ml/kg, respiratory rate: 14/min).",[Response of human growth hormone to anesthesia induction with propofol]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3063133/),1/[min],14,187266,DB01339,Vecuronium
,12131108,onset time of maximum effect,"With hypothermia, the central volume of distribution of neostigmine decreased by 38%, and onset time of maximum effect increased (4.6 vs. 5.6 min).",The influence of mild hypothermia on the pharmacokinetics and time course of action of neostigmine in anesthetized volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12131108/),min,4.6,192750,DB01339,Vecuronium
,12131108,onset time of maximum effect,"With hypothermia, the central volume of distribution of neostigmine decreased by 38%, and onset time of maximum effect increased (4.6 vs. 5.6 min).",The influence of mild hypothermia on the pharmacokinetics and time course of action of neostigmine in anesthetized volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12131108/),min,5.6,192751,DB01339,Vecuronium
,12131108,clearance,"Hypothermia did not change the clearance (696 ml/min), maximum effect, or duration of action of neostigmine.",The influence of mild hypothermia on the pharmacokinetics and time course of action of neostigmine in anesthetized volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12131108/),[ml] / [min],696,192752,DB01339,Vecuronium
,1675040,duration of action,"Also, in cats with liver failure, the duration of action and recovery index of 3-desacetylvecuronium was significantly greater than in control cats (168 +/- 62 vs. 82 +/- 32 min, and 39 +/- 19 vs. 10 +/- 4 min, respectively).","Pharmacokinetics, neuromuscular effects, and biodisposition of 3-desacetylvecuronium (Org 7268) in cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1675040/),min,168,192938,DB01339,Vecuronium
,1675040,recovery index,"Also, in cats with liver failure, the duration of action and recovery index of 3-desacetylvecuronium was significantly greater than in control cats (168 +/- 62 vs. 82 +/- 32 min, and 39 +/- 19 vs. 10 +/- 4 min, respectively).","Pharmacokinetics, neuromuscular effects, and biodisposition of 3-desacetylvecuronium (Org 7268) in cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1675040/),min,82,192939,DB01339,Vecuronium
,1675040,recovery index,"Also, in cats with liver failure, the duration of action and recovery index of 3-desacetylvecuronium was significantly greater than in control cats (168 +/- 62 vs. 82 +/- 32 min, and 39 +/- 19 vs. 10 +/- 4 min, respectively).","Pharmacokinetics, neuromuscular effects, and biodisposition of 3-desacetylvecuronium (Org 7268) in cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1675040/),min,39,192940,DB01339,Vecuronium
,1675040,recovery index,"Also, in cats with liver failure, the duration of action and recovery index of 3-desacetylvecuronium was significantly greater than in control cats (168 +/- 62 vs. 82 +/- 32 min, and 39 +/- 19 vs. 10 +/- 4 min, respectively).","Pharmacokinetics, neuromuscular effects, and biodisposition of 3-desacetylvecuronium (Org 7268) in cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1675040/),min,10,192941,DB01339,Vecuronium
,1675040,Total recovery,"Total recovery of 3-desacetylvecuronium, for all three groups, in urine, bile, and liver was 90 +/- 11% (mean +/- SD).","Pharmacokinetics, neuromuscular effects, and biodisposition of 3-desacetylvecuronium (Org 7268) in cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1675040/),%,90,192942,DB01339,Vecuronium
,1829656,Onset time until maximum block,"Onset time until maximum block, duration until 25% recovery of twitch height, and recovery from 25 until 75% of twitch height were 1.7 (32), 53 (19) and 20 (37) min, respectively.","The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),min,1.7,197004,DB01339,Vecuronium
,1829656,duration until,"Onset time until maximum block, duration until 25% recovery of twitch height, and recovery from 25 until 75% of twitch height were 1.7 (32), 53 (19) and 20 (37) min, respectively.","The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),min,53,197005,DB01339,Vecuronium
,1829656,Half lives,"Half lives were 1.8 (33), 19 (34), 131 (62) min, respectively, in a three exponential decay; distribution volume at steady-state and plasma clearance were 0.264 (56) L.kg-1 and 4.0 (21) ml.kg-1.min-1, respectively.","The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),min,1.8,197006,DB01339,Vecuronium
,1829656,Half lives,"Half lives were 1.8 (33), 19 (34), 131 (62) min, respectively, in a three exponential decay; distribution volume at steady-state and plasma clearance were 0.264 (56) L.kg-1 and 4.0 (21) ml.kg-1.min-1, respectively.","The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),min,19,197007,DB01339,Vecuronium
,1829656,Half lives,"Half lives were 1.8 (33), 19 (34), 131 (62) min, respectively, in a three exponential decay; distribution volume at steady-state and plasma clearance were 0.264 (56) L.kg-1 and 4.0 (21) ml.kg-1.min-1, respectively.","The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),min,131,197008,DB01339,Vecuronium
,1829656,distribution volume at steady-state,"Half lives were 1.8 (33), 19 (34), 131 (62) min, respectively, in a three exponential decay; distribution volume at steady-state and plasma clearance were 0.264 (56) L.kg-1 and 4.0 (21) ml.kg-1.min-1, respectively.","The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),[l] / [kg],0.264,197009,DB01339,Vecuronium
,1829656,plasma clearance,"Half lives were 1.8 (33), 19 (34), 131 (62) min, respectively, in a three exponential decay; distribution volume at steady-state and plasma clearance were 0.264 (56) L.kg-1 and 4.0 (21) ml.kg-1.min-1, respectively.","The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),[ml] / [kg·min],4.0,197010,DB01339,Vecuronium
,1829656,Plasma concentration at 25% recovery of the twitch height,Plasma concentration at 25% recovery of the twitch height was 1.0 mg.L-1.,"The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),[mg] / [l],1.0,197011,DB01339,Vecuronium
,2897176,time to attain 100% twitch depression (onset time),Only the time to attain 100% twitch depression (onset time) was prolonged in liver disease patients (2.8 +/- 0.7 min; mean +/- SD) as compared to control patients (1.9 +/- 0.4 min).,Vecuronium in alcoholic liver disease: a pharmacokinetic and pharmacodynamic analysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897176/),min,2.8,205186,DB01339,Vecuronium
,2897176,time to attain 100% twitch depression (onset time),Only the time to attain 100% twitch depression (onset time) was prolonged in liver disease patients (2.8 +/- 0.7 min; mean +/- SD) as compared to control patients (1.9 +/- 0.4 min).,Vecuronium in alcoholic liver disease: a pharmacokinetic and pharmacodynamic analysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897176/),min,1.9,205187,DB01339,Vecuronium
,2897176,time to the reappearance of twitch response,The time to the reappearance of twitch response was 32.7 +/- 9.7 min in patients with liver disease and 36.8 +/- 15.5 min in controls.,Vecuronium in alcoholic liver disease: a pharmacokinetic and pharmacodynamic analysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897176/),min,32.7,205188,DB01339,Vecuronium
,2897176,time to the reappearance of twitch response,The time to the reappearance of twitch response was 32.7 +/- 9.7 min in patients with liver disease and 36.8 +/- 15.5 min in controls.,Vecuronium in alcoholic liver disease: a pharmacokinetic and pharmacodynamic analysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897176/),min,36.8,205189,DB01339,Vecuronium
,10072020,clearance,The median clearance of rapacuronium was 7.28 mL x kg(-1) x min(-1) x with an excretion fraction in the urine of 6.2%.,Pharmacokinetics and pharmacokinetic-dynamic relationship between rapacuronium (Org 9487) and its 3-desacetyl metabolite (Org 9488). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10072020/),[ml] / [kg·min],7.28,211672,DB01339,Vecuronium
,10072020,excretion fraction in the urine,The median clearance of rapacuronium was 7.28 mL x kg(-1) x min(-1) x with an excretion fraction in the urine of 6.2%.,Pharmacokinetics and pharmacokinetic-dynamic relationship between rapacuronium (Org 9487) and its 3-desacetyl metabolite (Org 9488). ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10072020/),%,6.2,211673,DB01339,Vecuronium
,10072020,clearance,"The clearance (studied in two groups) of Org 9488 was 1.28 and 1.06 mL x kg(-1) x min(-1) with an excretion fraction in the urine of 51.9% and 53.5%, respectively.",Pharmacokinetics and pharmacokinetic-dynamic relationship between rapacuronium (Org 9487) and its 3-desacetyl metabolite (Org 9488). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10072020/),[ml] / [kg·min],1.28,211674,DB01339,Vecuronium
,10072020,clearance,"The clearance (studied in two groups) of Org 9488 was 1.28 and 1.06 mL x kg(-1) x min(-1) with an excretion fraction in the urine of 51.9% and 53.5%, respectively.",Pharmacokinetics and pharmacokinetic-dynamic relationship between rapacuronium (Org 9487) and its 3-desacetyl metabolite (Org 9488). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10072020/),[ml] / [kg·min],1.06,211675,DB01339,Vecuronium
,10072020,excretion fraction in the urine,"The clearance (studied in two groups) of Org 9488 was 1.28 and 1.06 mL x kg(-1) x min(-1) with an excretion fraction in the urine of 51.9% and 53.5%, respectively.",Pharmacokinetics and pharmacokinetic-dynamic relationship between rapacuronium (Org 9487) and its 3-desacetyl metabolite (Org 9488). ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10072020/),%,51.9,211676,DB01339,Vecuronium
,10072020,excretion fraction in the urine,"The clearance (studied in two groups) of Org 9488 was 1.28 and 1.06 mL x kg(-1) x min(-1) with an excretion fraction in the urine of 51.9% and 53.5%, respectively.",Pharmacokinetics and pharmacokinetic-dynamic relationship between rapacuronium (Org 9487) and its 3-desacetyl metabolite (Org 9488). ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10072020/),%,53.5,211677,DB01339,Vecuronium
,10072020,rate constant of transport,The median rate constant of transport between plasma and the biophase of rapacuronium (0.449 min(-1)) is markedly larger than that for Org 9488 (0.105 min(-1)).,Pharmacokinetics and pharmacokinetic-dynamic relationship between rapacuronium (Org 9487) and its 3-desacetyl metabolite (Org 9488). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10072020/),1/[min],0.449,211678,DB01339,Vecuronium
,10072020,rate constant of transport,The median rate constant of transport between plasma and the biophase of rapacuronium (0.449 min(-1)) is markedly larger than that for Org 9488 (0.105 min(-1)).,Pharmacokinetics and pharmacokinetic-dynamic relationship between rapacuronium (Org 9487) and its 3-desacetyl metabolite (Org 9488). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10072020/),1/[min],0.105,211679,DB01339,Vecuronium
,10072020,concentration,The modeled concentration in the biophase at 50% effect as a measure of potency is higher for rapacuronium (4.70 microg/mL) than for Org 9488 (1.83 microg/mL).,Pharmacokinetics and pharmacokinetic-dynamic relationship between rapacuronium (Org 9487) and its 3-desacetyl metabolite (Org 9488). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10072020/),,1.83,211680,DB01339,Vecuronium
,8095780,ED50,"The results demonstrated a sevenfold increase in sensitivity (reducing the ED50 from 24 micrograms/kg to 3.5 micrograms/kg) to vecuronium when it was administered following recovery from decamethonium block, and a partial reversal lf the vecuronium block by decamethonium when the decamethonium was administered during recovery from vecuronium block.",Potentiation and antagonism of vecuronium by decamethonium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095780/),[μg] / [kg],24,213252,DB01339,Vecuronium
,8095780,ED50,"The results demonstrated a sevenfold increase in sensitivity (reducing the ED50 from 24 micrograms/kg to 3.5 micrograms/kg) to vecuronium when it was administered following recovery from decamethonium block, and a partial reversal lf the vecuronium block by decamethonium when the decamethonium was administered during recovery from vecuronium block.",Potentiation and antagonism of vecuronium by decamethonium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095780/),[μg] / [kg],3.5,213253,DB01339,Vecuronium
,10691223,Plasma clearance,Plasma clearance was 4.77 ml x kg(-1) x min(-1) + 8.48 ml/min.,Pharmacokinetics of rapacuronium in infants and children with intravenous and intramuscular administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691223/),[ml] / [kg·min],4.77,217774,DB01339,Vecuronium
,10691223,Plasma clearance,Plasma clearance was 4.77 ml x kg(-1) x min(-1) + 8.48 ml/min.,Pharmacokinetics of rapacuronium in infants and children with intravenous and intramuscular administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691223/),[ml] / [min],8.48,217775,DB01339,Vecuronium
,10691223,Intramuscular bioavailability,Intramuscular bioavailability averaged 56%.,Pharmacokinetics of rapacuronium in infants and children with intravenous and intramuscular administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691223/),%,56,217776,DB01339,Vecuronium
,10691223,rate constants,Absorption from the intramuscular depot had two rate constants: 0.0491 min(-1) (72.4% of absorbed drug) and 0.0110 min(-1) (27.6% of the absorbed drug).,Pharmacokinetics of rapacuronium in infants and children with intravenous and intramuscular administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691223/),1/[min],0.0491,217777,DB01339,Vecuronium
,10691223,rate constants,Absorption from the intramuscular depot had two rate constants: 0.0491 min(-1) (72.4% of absorbed drug) and 0.0110 min(-1) (27.6% of the absorbed drug).,Pharmacokinetics of rapacuronium in infants and children with intravenous and intramuscular administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691223/),%,72.,217778,DB01339,Vecuronium
,10691223,rate constants,Absorption from the intramuscular depot had two rate constants: 0.0491 min(-1) (72.4% of absorbed drug) and 0.0110 min(-1) (27.6% of the absorbed drug).,Pharmacokinetics of rapacuronium in infants and children with intravenous and intramuscular administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691223/),1/[min],0.0110,217779,DB01339,Vecuronium
,10691223,bioavailability,"After intramuscular administration, bioavailability is 56%, and plasma rapacuronium concentrations peak within 4 or 5 min.",Pharmacokinetics of rapacuronium in infants and children with intravenous and intramuscular administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691223/),%,56,217780,DB01339,Vecuronium
,17580185,total gas flow,"Anesthesia was maintained with sevoflurane (2%), O(2), and N(2)O at a total gas flow of 6 L . min(-1) using a semiclosed circle system with a sodalime canister.",Renal safety and extrahepatic defluorination of sevoflurane in hepatic transplantations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17580185/),[l] / [min],6,221315,DB01339,Vecuronium
,17580185,duration of surgery,Mean duration of surgery was 9:06 +/- 0:09 hours.,Renal safety and extrahepatic defluorination of sevoflurane in hepatic transplantations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17580185/),h,9:06,221316,DB01339,Vecuronium
,11176092,concentrations,"Hypothermia increased vecuronium concentrations in the perfusion medium from 4.0 microg/ml (range, 2.5-6.6) to 15.6 microg/ml (11.5-18.4 microg/ml; P = 0.018).",Effect of hypothermia on the hepatic uptake and biliary excretion of vecuronium in the isolated perfused rat liver. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11176092/),[μg] / [ml],4.0,224083,DB01339,Vecuronium
,11176092,concentrations,"Hypothermia increased vecuronium concentrations in the perfusion medium from 4.0 microg/ml (range, 2.5-6.6) to 15.6 microg/ml (11.5-18.4 microg/ml; P = 0.018).",Effect of hypothermia on the hepatic uptake and biliary excretion of vecuronium in the isolated perfused rat liver. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11176092/),[μg] / [ml],15.6,224084,DB01339,Vecuronium
,2576345,elimination half-life,"Mean elimination half-life was 215.3 +/- 78.4 min, and the apparent final volume of distribution was 0.58 +/- 0.20 l.kg-1.",[Pharmacokinetics of dextromoramide in the surgical patient]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576345/),min,215.3,225764,DB01339,Vecuronium
,2576345,apparent final volume of distribution,"Mean elimination half-life was 215.3 +/- 78.4 min, and the apparent final volume of distribution was 0.58 +/- 0.20 l.kg-1.",[Pharmacokinetics of dextromoramide in the surgical patient]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576345/),[l] / [kg],0.58,225765,DB01339,Vecuronium
,2576345,systemic clearance,"Hepatic extraction was low, as shown by a mean systemic clearance of 2.0 +/- 0.9 ml.kg-1.min-1.",[Pharmacokinetics of dextromoramide in the surgical patient]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576345/),[ml] / [kg·min],2.0,225766,DB01339,Vecuronium
,2898986,ED90,"For vecuronium the ED90 was (mean +/- SE) 0.034 +/- 0.002 (SD), 0.037 +/- 0.003 (CD), and 0.036 +/- 0.003 mg/kg (CDI).",Cumulative dose-response with infusion: a technique to determine neuromuscular blocking potency of atracurium and vecuronium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898986/),[mg] / [kg],0.034,225767,DB01339,Vecuronium
,2898986,ED90,"For vecuronium the ED90 was (mean +/- SE) 0.034 +/- 0.002 (SD), 0.037 +/- 0.003 (CD), and 0.036 +/- 0.003 mg/kg (CDI).",Cumulative dose-response with infusion: a technique to determine neuromuscular blocking potency of atracurium and vecuronium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898986/),[mg] / [kg],0.037,225768,DB01339,Vecuronium
,2898986,ED90,"For vecuronium the ED90 was (mean +/- SE) 0.034 +/- 0.002 (SD), 0.037 +/- 0.003 (CD), and 0.036 +/- 0.003 mg/kg (CDI).",Cumulative dose-response with infusion: a technique to determine neuromuscular blocking potency of atracurium and vecuronium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898986/),[mg] / [kg],0.036,225769,DB01339,Vecuronium
,2898986,ED90,"For atracurium the ED90 was 0.175 +/- 0.009 (SD), 0.206 +/- 0.019 (CD), and 0.179 +/- 0.015 mg/kg (CDI).",Cumulative dose-response with infusion: a technique to determine neuromuscular blocking potency of atracurium and vecuronium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898986/),[mg] / [kg],0.175,225770,DB01339,Vecuronium
,2898986,ED90,"For atracurium the ED90 was 0.175 +/- 0.009 (SD), 0.206 +/- 0.019 (CD), and 0.179 +/- 0.015 mg/kg (CDI).",Cumulative dose-response with infusion: a technique to determine neuromuscular blocking potency of atracurium and vecuronium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898986/),[mg] / [kg],0.206,225771,DB01339,Vecuronium
,2898986,ED90,"For atracurium the ED90 was 0.175 +/- 0.009 (SD), 0.206 +/- 0.019 (CD), and 0.179 +/- 0.015 mg/kg (CDI).",Cumulative dose-response with infusion: a technique to determine neuromuscular blocking potency of atracurium and vecuronium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898986/),[mg] / [kg],0.179,225772,DB01339,Vecuronium
,8610903,infusion rate requirements to achieve 90% muscle relaxation,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),1/[min·μgram-kg],0.42,227640,DB01339,Vecuronium
,8610903,infusion rate requirements to achieve 90% muscle relaxation,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),1/[min·μgram-kg],0.40,227641,DB01339,Vecuronium
,8610903,CVEC,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),[ng] / [ml],144.4,227642,DB01339,Vecuronium
,8610903,CVEC,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),[ng] / [ml],149.7,227643,DB01339,Vecuronium
,8610903,CDES,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),[ng] / [ml],57.2,227644,DB01339,Vecuronium
,8610903,CDES,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),[ng] / [ml],65.3,227645,DB01339,Vecuronium
,8610903,clearance,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),[ml] / [kg·min],2.85,227646,DB01339,Vecuronium
,8610903,clearance,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),[ml] / [kg·min],3.19,227647,DB01339,Vecuronium
,7910526,ED90,"The ED90 values for Org 9453, Org 9489 and Org 9487 were 1.4, 0.45 and 1.15 mg.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),mg,1.4,229332,DB01339,Vecuronium
,7910526,ED90,"The ED90 values for Org 9453, Org 9489 and Org 9487 were 1.4, 0.45 and 1.15 mg.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),mg,0.45,229333,DB01339,Vecuronium
,7910526,ED90,"The ED90 values for Org 9453, Org 9489 and Org 9487 were 1.4, 0.45 and 1.15 mg.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),mg,1.15,229334,DB01339,Vecuronium
,7910526,onset times,"The onset times of Org 9453 (1.5 mg.kg-1, 1.1 X ED90), Org 9489 (0.9 mg.kg-1, 2 X ED90) and Org 9487 (1.5 mg.kg-1, 1.3 X ED90) were 1.2, 1.6 and 1.5 min, and the durations until 25% twitch recovery were 8.6, 22.0 and 8.9 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),min,1.2,229335,DB01339,Vecuronium
,7910526,onset times,"The onset times of Org 9453 (1.5 mg.kg-1, 1.1 X ED90), Org 9489 (0.9 mg.kg-1, 2 X ED90) and Org 9487 (1.5 mg.kg-1, 1.3 X ED90) were 1.2, 1.6 and 1.5 min, and the durations until 25% twitch recovery were 8.6, 22.0 and 8.9 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),min,1.6,229336,DB01339,Vecuronium
,7910526,onset times,"The onset times of Org 9453 (1.5 mg.kg-1, 1.1 X ED90), Org 9489 (0.9 mg.kg-1, 2 X ED90) and Org 9487 (1.5 mg.kg-1, 1.3 X ED90) were 1.2, 1.6 and 1.5 min, and the durations until 25% twitch recovery were 8.6, 22.0 and 8.9 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),min,1.5,229337,DB01339,Vecuronium
,7910526,durations until 25% twitch recovery,"The onset times of Org 9453 (1.5 mg.kg-1, 1.1 X ED90), Org 9489 (0.9 mg.kg-1, 2 X ED90) and Org 9487 (1.5 mg.kg-1, 1.3 X ED90) were 1.2, 1.6 and 1.5 min, and the durations until 25% twitch recovery were 8.6, 22.0 and 8.9 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),min,8.6,229338,DB01339,Vecuronium
,7910526,durations until 25% twitch recovery,"The onset times of Org 9453 (1.5 mg.kg-1, 1.1 X ED90), Org 9489 (0.9 mg.kg-1, 2 X ED90) and Org 9487 (1.5 mg.kg-1, 1.3 X ED90) were 1.2, 1.6 and 1.5 min, and the durations until 25% twitch recovery were 8.6, 22.0 and 8.9 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),min,22.0,229339,DB01339,Vecuronium
,7910526,durations until 25% twitch recovery,"The onset times of Org 9453 (1.5 mg.kg-1, 1.1 X ED90), Org 9489 (0.9 mg.kg-1, 2 X ED90) and Org 9487 (1.5 mg.kg-1, 1.3 X ED90) were 1.2, 1.6 and 1.5 min, and the durations until 25% twitch recovery were 8.6, 22.0 and 8.9 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),min,8.9,229340,DB01339,Vecuronium
,7910526,Clearances,"Clearances of these doses were 6.9, 5.8, and 11.1 ml.kg-1.min-1, and mean residence times 26, 79, and 41 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),[ml] / [kg·min],6.9,229341,DB01339,Vecuronium
,7910526,Clearances,"Clearances of these doses were 6.9, 5.8, and 11.1 ml.kg-1.min-1, and mean residence times 26, 79, and 41 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),[ml] / [kg·min],5.8,229342,DB01339,Vecuronium
,7910526,Clearances,"Clearances of these doses were 6.9, 5.8, and 11.1 ml.kg-1.min-1, and mean residence times 26, 79, and 41 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),[ml] / [kg·min],11.1,229343,DB01339,Vecuronium
,7910526,mean residence times,"Clearances of these doses were 6.9, 5.8, and 11.1 ml.kg-1.min-1, and mean residence times 26, 79, and 41 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),min,26,229344,DB01339,Vecuronium
,7910526,mean residence times,"Clearances of these doses were 6.9, 5.8, and 11.1 ml.kg-1.min-1, and mean residence times 26, 79, and 41 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),min,79,229345,DB01339,Vecuronium
,7910526,mean residence times,"Clearances of these doses were 6.9, 5.8, and 11.1 ml.kg-1.min-1, and mean residence times 26, 79, and 41 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),min,41,229346,DB01339,Vecuronium
,7910526,renal excretion,"Mean renal excretion (parent compound and metabolites) within 24 hr amounted to 5, 11.3 and 12.2% respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),%,5,229347,DB01339,Vecuronium
,7910526,renal excretion,"Mean renal excretion (parent compound and metabolites) within 24 hr amounted to 5, 11.3 and 12.2% respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),%,11.3,229348,DB01339,Vecuronium
,7910526,renal excretion,"Mean renal excretion (parent compound and metabolites) within 24 hr amounted to 5, 11.3 and 12.2% respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),%,12.2,229349,DB01339,Vecuronium
,1677546,50% recovery time,"Spontaneous recovery was significantly longer in elderly patients than in younger patients (50% recovery time, 97.1 +/- 29 vs 39.8 +/- 14 min, mean +/- SD; recovery index [25%-75%], 49.4 +/- 11 vs 15.0 +/- 8 min).","Distribution, elimination, and action of vecuronium in the elderly. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1677546/),min,97.1,229394,DB01339,Vecuronium
,1677546,50% recovery time,"Spontaneous recovery was significantly longer in elderly patients than in younger patients (50% recovery time, 97.1 +/- 29 vs 39.8 +/- 14 min, mean +/- SD; recovery index [25%-75%], 49.4 +/- 11 vs 15.0 +/- 8 min).","Distribution, elimination, and action of vecuronium in the elderly. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1677546/),min,39.8,229395,DB01339,Vecuronium
,1677546,recovery index,"Spontaneous recovery was significantly longer in elderly patients than in younger patients (50% recovery time, 97.1 +/- 29 vs 39.8 +/- 14 min, mean +/- SD; recovery index [25%-75%], 49.4 +/- 11 vs 15.0 +/- 8 min).","Distribution, elimination, and action of vecuronium in the elderly. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1677546/),min,25,229396,DB01339,Vecuronium
,1677546,recovery index,"Spontaneous recovery was significantly longer in elderly patients than in younger patients (50% recovery time, 97.1 +/- 29 vs 39.8 +/- 14 min, mean +/- SD; recovery index [25%-75%], 49.4 +/- 11 vs 15.0 +/- 8 min).","Distribution, elimination, and action of vecuronium in the elderly. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1677546/),min,75,229397,DB01339,Vecuronium
,1677546,recovery index,"Spontaneous recovery was significantly longer in elderly patients than in younger patients (50% recovery time, 97.1 +/- 29 vs 39.8 +/- 14 min, mean +/- SD; recovery index [25%-75%], 49.4 +/- 11 vs 15.0 +/- 8 min).","Distribution, elimination, and action of vecuronium in the elderly. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1677546/),min,49.4,229398,DB01339,Vecuronium
,1677546,recovery index,"Spontaneous recovery was significantly longer in elderly patients than in younger patients (50% recovery time, 97.1 +/- 29 vs 39.8 +/- 14 min, mean +/- SD; recovery index [25%-75%], 49.4 +/- 11 vs 15.0 +/- 8 min).","Distribution, elimination, and action of vecuronium in the elderly. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1677546/),min,15.0,229399,DB01339,Vecuronium
,1677546,elimination half-life,"In addition, in elderly patients elimination half-life of vecuronium was significantly prolonged (125 +/- 55 vs 78 +/- 21 min, P = 0.04) and plasma clearance reduced (2.6 +/- 0.6 vs 5.6 +/- 3.2 mL.kg-1.min-1, P = 0.049).","Distribution, elimination, and action of vecuronium in the elderly. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1677546/),min,125,229400,DB01339,Vecuronium
,1677546,elimination half-life,"In addition, in elderly patients elimination half-life of vecuronium was significantly prolonged (125 +/- 55 vs 78 +/- 21 min, P = 0.04) and plasma clearance reduced (2.6 +/- 0.6 vs 5.6 +/- 3.2 mL.kg-1.min-1, P = 0.049).","Distribution, elimination, and action of vecuronium in the elderly. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1677546/),min,78,229401,DB01339,Vecuronium
,1677546,plasma clearance,"In addition, in elderly patients elimination half-life of vecuronium was significantly prolonged (125 +/- 55 vs 78 +/- 21 min, P = 0.04) and plasma clearance reduced (2.6 +/- 0.6 vs 5.6 +/- 3.2 mL.kg-1.min-1, P = 0.049).","Distribution, elimination, and action of vecuronium in the elderly. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1677546/),[ml] / [kg·min],2.6,229402,DB01339,Vecuronium
,1677546,plasma clearance,"In addition, in elderly patients elimination half-life of vecuronium was significantly prolonged (125 +/- 55 vs 78 +/- 21 min, P = 0.04) and plasma clearance reduced (2.6 +/- 0.6 vs 5.6 +/- 3.2 mL.kg-1.min-1, P = 0.049).","Distribution, elimination, and action of vecuronium in the elderly. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1677546/),[ml] / [kg·min],5.6,229403,DB01339,Vecuronium
,10551581,central volume of distribution,"The central volume of distribution was increased to 131 (104-141) ml/kg in patients with cirrhosis (P < 0.01), compared with 75 (47-146) ml/kg in controls.",Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),[ml] / [kg],131,237005,DB01339,Vecuronium
,10551581,central volume of distribution,"The central volume of distribution was increased to 131 (104-141) ml/kg in patients with cirrhosis (P < 0.01), compared with 75 (47-146) ml/kg in controls.",Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),[ml] / [kg],75,237006,DB01339,Vecuronium
,10551581,total apparent volume of distribution,"The total apparent volume of distribution was also increased (P < 0.05) to 331 (284-488) ml/kg in patients with cirrhosis, compared with 221 (124-285) ml/kg in controls.",Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),[ml] / [kg],331,237007,DB01339,Vecuronium
,10551581,total apparent volume of distribution,"The total apparent volume of distribution was also increased (P < 0.05) to 331 (284-488) ml/kg in patients with cirrhosis, compared with 221 (124-285) ml/kg in controls.",Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),[ml] / [kg],221,237008,DB01339,Vecuronium
,10551581,elimination half-life,The elimination half-life was 88 (77-102) min in controls and 90 (76-117) min in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),min,88,237009,DB01339,Vecuronium
,10551581,elimination half-life,The elimination half-life was 88 (77-102) min in controls and 90 (76-117) min in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),min,90,237010,DB01339,Vecuronium
,10551581,Plasma clearance,"Plasma clearance was increased (P < 0.05) to 6.9 (6.1-8.9) ml x min(-1) x kg(-1) in patients with cirrhosis, compared with 5.3 (4.2-8.4) ml x min(-1) x kg(-1) in controls.",Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),[ml] / [kg·min],6.9,237011,DB01339,Vecuronium
,10551581,Plasma clearance,"Plasma clearance was increased (P < 0.05) to 6.9 (6.1-8.9) ml x min(-1) x kg(-1) in patients with cirrhosis, compared with 5.3 (4.2-8.4) ml x min(-1) x kg(-1) in controls.",Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),[ml] / [kg·min],5.3,237012,DB01339,Vecuronium
,10551581,Onset time,Onset time was 65 (40-110) s in controls and of 60 (52-240) s in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),s,65,237013,DB01339,Vecuronium
,10551581,Onset time,Onset time was 65 (40-110) s in controls and of 60 (52-240) s in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),s,60,237014,DB01339,Vecuronium
,10551581,Time to return to 90%,Time to return to 90% of thumb adduction force control value was of 49 (28-80) min in controls and 47 (28-71) min in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),min,49,237015,DB01339,Vecuronium
,10551581,Time to return to 90%,Time to return to 90% of thumb adduction force control value was of 49 (28-80) min in controls and 47 (28-71) min in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),min,47,237016,DB01339,Vecuronium
,7932174,plasma clearance,"3-Desacetylvecuronium, compared with vecuronium (median, range in parentheses), had a smaller plasma clearance, 3.51 (2.11-6.57) vs. 5.39 (5.04-7.19) ml.kg-1.min-1; a larger steady-state distribution volume, 254 (215-410) vs. 152 (111-170) ml.kg-1; a longer terminal elimination half-life 116 (44-672) vs. 34 (25-61) min and a longer mean residence time, 67 (42-145) vs. 26 (18-32) min (P < .05).","The pharmacodynamics and pharmacokinetics of the metabolite 3-desacetylvecuronium (ORG 7268) and its parent compound, vecuronium, in human volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7932174/),[ml] / [kg·min],3.51,238107,DB01339,Vecuronium
,7932174,plasma clearance,"3-Desacetylvecuronium, compared with vecuronium (median, range in parentheses), had a smaller plasma clearance, 3.51 (2.11-6.57) vs. 5.39 (5.04-7.19) ml.kg-1.min-1; a larger steady-state distribution volume, 254 (215-410) vs. 152 (111-170) ml.kg-1; a longer terminal elimination half-life 116 (44-672) vs. 34 (25-61) min and a longer mean residence time, 67 (42-145) vs. 26 (18-32) min (P < .05).","The pharmacodynamics and pharmacokinetics of the metabolite 3-desacetylvecuronium (ORG 7268) and its parent compound, vecuronium, in human volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7932174/),[ml] / [kg·min],5.39,238108,DB01339,Vecuronium
,7932174,steady-state distribution volume,"3-Desacetylvecuronium, compared with vecuronium (median, range in parentheses), had a smaller plasma clearance, 3.51 (2.11-6.57) vs. 5.39 (5.04-7.19) ml.kg-1.min-1; a larger steady-state distribution volume, 254 (215-410) vs. 152 (111-170) ml.kg-1; a longer terminal elimination half-life 116 (44-672) vs. 34 (25-61) min and a longer mean residence time, 67 (42-145) vs. 26 (18-32) min (P < .05).","The pharmacodynamics and pharmacokinetics of the metabolite 3-desacetylvecuronium (ORG 7268) and its parent compound, vecuronium, in human volunteers. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7932174/),[ml] / [kg],254,238109,DB01339,Vecuronium
,7932174,steady-state distribution volume,"3-Desacetylvecuronium, compared with vecuronium (median, range in parentheses), had a smaller plasma clearance, 3.51 (2.11-6.57) vs. 5.39 (5.04-7.19) ml.kg-1.min-1; a larger steady-state distribution volume, 254 (215-410) vs. 152 (111-170) ml.kg-1; a longer terminal elimination half-life 116 (44-672) vs. 34 (25-61) min and a longer mean residence time, 67 (42-145) vs. 26 (18-32) min (P < .05).","The pharmacodynamics and pharmacokinetics of the metabolite 3-desacetylvecuronium (ORG 7268) and its parent compound, vecuronium, in human volunteers. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7932174/),[ml] / [kg],152,238110,DB01339,Vecuronium
,7932174,terminal elimination half-life,"3-Desacetylvecuronium, compared with vecuronium (median, range in parentheses), had a smaller plasma clearance, 3.51 (2.11-6.57) vs. 5.39 (5.04-7.19) ml.kg-1.min-1; a larger steady-state distribution volume, 254 (215-410) vs. 152 (111-170) ml.kg-1; a longer terminal elimination half-life 116 (44-672) vs. 34 (25-61) min and a longer mean residence time, 67 (42-145) vs. 26 (18-32) min (P < .05).","The pharmacodynamics and pharmacokinetics of the metabolite 3-desacetylvecuronium (ORG 7268) and its parent compound, vecuronium, in human volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7932174/),min,116,238111,DB01339,Vecuronium
,7932174,terminal elimination half-life,"3-Desacetylvecuronium, compared with vecuronium (median, range in parentheses), had a smaller plasma clearance, 3.51 (2.11-6.57) vs. 5.39 (5.04-7.19) ml.kg-1.min-1; a larger steady-state distribution volume, 254 (215-410) vs. 152 (111-170) ml.kg-1; a longer terminal elimination half-life 116 (44-672) vs. 34 (25-61) min and a longer mean residence time, 67 (42-145) vs. 26 (18-32) min (P < .05).","The pharmacodynamics and pharmacokinetics of the metabolite 3-desacetylvecuronium (ORG 7268) and its parent compound, vecuronium, in human volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7932174/),min,34,238112,DB01339,Vecuronium
,7932174,mean residence time,"3-Desacetylvecuronium, compared with vecuronium (median, range in parentheses), had a smaller plasma clearance, 3.51 (2.11-6.57) vs. 5.39 (5.04-7.19) ml.kg-1.min-1; a larger steady-state distribution volume, 254 (215-410) vs. 152 (111-170) ml.kg-1; a longer terminal elimination half-life 116 (44-672) vs. 34 (25-61) min and a longer mean residence time, 67 (42-145) vs. 26 (18-32) min (P < .05).","The pharmacodynamics and pharmacokinetics of the metabolite 3-desacetylvecuronium (ORG 7268) and its parent compound, vecuronium, in human volunteers. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7932174/),min,67,238113,DB01339,Vecuronium
,7932174,mean residence time,"3-Desacetylvecuronium, compared with vecuronium (median, range in parentheses), had a smaller plasma clearance, 3.51 (2.11-6.57) vs. 5.39 (5.04-7.19) ml.kg-1.min-1; a larger steady-state distribution volume, 254 (215-410) vs. 152 (111-170) ml.kg-1; a longer terminal elimination half-life 116 (44-672) vs. 34 (25-61) min and a longer mean residence time, 67 (42-145) vs. 26 (18-32) min (P < .05).","The pharmacodynamics and pharmacokinetics of the metabolite 3-desacetylvecuronium (ORG 7268) and its parent compound, vecuronium, in human volunteers. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7932174/),min,26,238114,DB01339,Vecuronium
,7932174,Renal clearances,"Renal clearances of 3-desacetylvecuronium and vecuronium were 0.85 (0.15-1.24) and 0.58 (0.16-0.66) ml.kg-1.min-1, respectively (P < .05).","The pharmacodynamics and pharmacokinetics of the metabolite 3-desacetylvecuronium (ORG 7268) and its parent compound, vecuronium, in human volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7932174/),[ml] / [kg·min],0.85,238115,DB01339,Vecuronium
,7932174,Renal clearances,"Renal clearances of 3-desacetylvecuronium and vecuronium were 0.85 (0.15-1.24) and 0.58 (0.16-0.66) ml.kg-1.min-1, respectively (P < .05).","The pharmacodynamics and pharmacokinetics of the metabolite 3-desacetylvecuronium (ORG 7268) and its parent compound, vecuronium, in human volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7932174/),[ml] / [kg·min],0.58,238116,DB01339,Vecuronium
,7932174,Concentrations,"Concentrations of 3-desacetylvecuronium and vecuronium that produced 50% neuromuscular block were 123 (109-154) and 102 (71-123) ng.ml-1, respectively (P < .05).","The pharmacodynamics and pharmacokinetics of the metabolite 3-desacetylvecuronium (ORG 7268) and its parent compound, vecuronium, in human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7932174/),[ng] / [ml],123,238117,DB01339,Vecuronium
,7932174,Concentrations,"Concentrations of 3-desacetylvecuronium and vecuronium that produced 50% neuromuscular block were 123 (109-154) and 102 (71-123) ng.ml-1, respectively (P < .05).","The pharmacodynamics and pharmacokinetics of the metabolite 3-desacetylvecuronium (ORG 7268) and its parent compound, vecuronium, in human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7932174/),[ng] / [ml],102,238118,DB01339,Vecuronium
,7914736,blood clearance,"Propofol blood clearance was 29.8 +/- 6.51 ml/min/kg, and volume of distribution was 3.60 +/- 1.34 L/kg, resulting in a blood elimination half-life of 144 +/- 46 minutes.",Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7914736/),[ml] / [kg·min],29.8,240059,DB01339,Vecuronium
,7914736,volume of distribution,"Propofol blood clearance was 29.8 +/- 6.51 ml/min/kg, and volume of distribution was 3.60 +/- 1.34 L/kg, resulting in a blood elimination half-life of 144 +/- 46 minutes.",Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7914736/),[l] / [kg],3.60,240060,DB01339,Vecuronium
,7914736,blood elimination half-life,"Propofol blood clearance was 29.8 +/- 6.51 ml/min/kg, and volume of distribution was 3.60 +/- 1.34 L/kg, resulting in a blood elimination half-life of 144 +/- 46 minutes.",Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7914736/),min,144,240061,DB01339,Vecuronium
,10223167,clearance,It has a low clearance (0.16 L/h/kg) and long elimination half-life (120 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.16,240354,DB01339,Vecuronium
,10223167,elimination half-life,It has a low clearance (0.16 L/h/kg) and long elimination half-life (120 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,120,240355,DB01339,Vecuronium
,10223167,clearance,"Its clearance (0.27 L/h/kg) is intermediate between those of pipecuronium and rapacuronium, but its elimination half-life is long (83 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.27,240356,DB01339,Vecuronium
,10223167,elimination half-life,"Its clearance (0.27 L/h/kg) is intermediate between those of pipecuronium and rapacuronium, but its elimination half-life is long (83 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,83,240357,DB01339,Vecuronium
,10223167,clearance,It has a high clearance (0.59 L/h/kg) but a long elimination half-life (112 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.59,240358,DB01339,Vecuronium
,10223167,elimination half-life,It has a high clearance (0.59 L/h/kg) but a long elimination half-life (112 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,112,240359,DB01339,Vecuronium
,10223167,clearance,"In adults, it has a low clearance (0.15 L/h/kg) and long elimination half-life (87 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.15,240360,DB01339,Vecuronium
,10223167,elimination half-life,"In adults, it has a low clearance (0.15 L/h/kg) and long elimination half-life (87 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,87,240361,DB01339,Vecuronium
,10223167,clearance,The 2 active isomers (cis-trans and trans-trans) have a high clearance (4.74 L/h/kg) and very short elimination half-lives (approximately 2 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],4.74,240362,DB01339,Vecuronium
,10223167,elimination half-lives,The 2 active isomers (cis-trans and trans-trans) have a high clearance (4.74 L/h/kg) and very short elimination half-lives (approximately 2 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,2,240363,DB01339,Vecuronium
,10223167,clearance,Cisatracurium has an intermediate clearance (0.3 L/h/kg) and short elimination half-life (26 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.3,240364,DB01339,Vecuronium
,10223167,elimination half-life,Cisatracurium has an intermediate clearance (0.3 L/h/kg) and short elimination half-life (26 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,26,240365,DB01339,Vecuronium
,2875680,5-25% recovery time,"When the dose of vecuronium was increased from 40 to 80 micrograms/kg, 5-25% recovery time increased from 6.0 +/- 2.5 min to 8.8 +/- 4.0 min (mean +/- SD) and 25-75% recovery time increased from 8.7 +/- 4.3 min to 12.6 +/- 4.4 min.",A pharmacokinetic explanation for increasing recovery time following larger or repeated doses of nondepolarizing muscle relaxants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875680/),min,6.0,242933,DB01339,Vecuronium
,2875680,5-25% recovery time,"When the dose of vecuronium was increased from 40 to 80 micrograms/kg, 5-25% recovery time increased from 6.0 +/- 2.5 min to 8.8 +/- 4.0 min (mean +/- SD) and 25-75% recovery time increased from 8.7 +/- 4.3 min to 12.6 +/- 4.4 min.",A pharmacokinetic explanation for increasing recovery time following larger or repeated doses of nondepolarizing muscle relaxants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875680/),min,8.8,242934,DB01339,Vecuronium
,2875680,25-75% recovery time,"When the dose of vecuronium was increased from 40 to 80 micrograms/kg, 5-25% recovery time increased from 6.0 +/- 2.5 min to 8.8 +/- 4.0 min (mean +/- SD) and 25-75% recovery time increased from 8.7 +/- 4.3 min to 12.6 +/- 4.4 min.",A pharmacokinetic explanation for increasing recovery time following larger or repeated doses of nondepolarizing muscle relaxants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875680/),min,8.7,242935,DB01339,Vecuronium
,2875680,25-75% recovery time,"When the dose of vecuronium was increased from 40 to 80 micrograms/kg, 5-25% recovery time increased from 6.0 +/- 2.5 min to 8.8 +/- 4.0 min (mean +/- SD) and 25-75% recovery time increased from 8.7 +/- 4.3 min to 12.6 +/- 4.4 min.",A pharmacokinetic explanation for increasing recovery time following larger or repeated doses of nondepolarizing muscle relaxants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875680/),min,12.6,242936,DB01339,Vecuronium
,9061114,T1,"In Group I, after release of the tourniquet, T1 and TOF recovery rate decreased significantly over a 10-min period (10% +/- 3 to 4% +/- 4 and 0.12 +/- 0.06 to 0.06 +/- 0.04, mean +/- SD, respectively); in Group II, T1 and TOF recovery rate increased significantly over a 10-min period following deflation of the tourniquet (10% +/- 6 to 14% +/- 7 and 0.10 +/- 0.03 to 0.18 +/- 0.02, respectively).",Sequestration of vecuronium bromide during extremity surgery involving use of a pneumatic tourniquet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9061114/),,4,246981,DB01339,Vecuronium
,9061114,T1,"In Group I, after release of the tourniquet, T1 and TOF recovery rate decreased significantly over a 10-min period (10% +/- 3 to 4% +/- 4 and 0.12 +/- 0.06 to 0.06 +/- 0.04, mean +/- SD, respectively); in Group II, T1 and TOF recovery rate increased significantly over a 10-min period following deflation of the tourniquet (10% +/- 6 to 14% +/- 7 and 0.10 +/- 0.03 to 0.18 +/- 0.02, respectively).",Sequestration of vecuronium bromide during extremity surgery involving use of a pneumatic tourniquet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9061114/),,10,246982,DB01339,Vecuronium
,9061114,T1,"In Group I, after release of the tourniquet, T1 and TOF recovery rate decreased significantly over a 10-min period (10% +/- 3 to 4% +/- 4 and 0.12 +/- 0.06 to 0.06 +/- 0.04, mean +/- SD, respectively); in Group II, T1 and TOF recovery rate increased significantly over a 10-min period following deflation of the tourniquet (10% +/- 6 to 14% +/- 7 and 0.10 +/- 0.03 to 0.18 +/- 0.02, respectively).",Sequestration of vecuronium bromide during extremity surgery involving use of a pneumatic tourniquet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9061114/),,14,246983,DB01339,Vecuronium
,9061114,T1,"In Group I, after release of the tourniquet, T1 and TOF recovery rate decreased significantly over a 10-min period (10% +/- 3 to 4% +/- 4 and 0.12 +/- 0.06 to 0.06 +/- 0.04, mean +/- SD, respectively); in Group II, T1 and TOF recovery rate increased significantly over a 10-min period following deflation of the tourniquet (10% +/- 6 to 14% +/- 7 and 0.10 +/- 0.03 to 0.18 +/- 0.02, respectively).",Sequestration of vecuronium bromide during extremity surgery involving use of a pneumatic tourniquet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9061114/),,0,246984,DB01339,Vecuronium
,9061114,TOF,"In Group I, after release of the tourniquet, T1 and TOF recovery rate decreased significantly over a 10-min period (10% +/- 3 to 4% +/- 4 and 0.12 +/- 0.06 to 0.06 +/- 0.04, mean +/- SD, respectively); in Group II, T1 and TOF recovery rate increased significantly over a 10-min period following deflation of the tourniquet (10% +/- 6 to 14% +/- 7 and 0.10 +/- 0.03 to 0.18 +/- 0.02, respectively).",Sequestration of vecuronium bromide during extremity surgery involving use of a pneumatic tourniquet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9061114/),,14,246985,DB01339,Vecuronium
,2875724,plasma clearance,The plasma clearance of vecuronium was decreased significantly (P less than 0.01) from 4.30 +/- 1.56 ml min-1 kg-1 (mean +/- SD) in normal patients to 2.36 +/- 0.80 ml min-1 kg-1 in patients with cholestasis.,Pharmacokinetics and pharmacodynamics of vecuronium in patients with cholestasis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875724/),[ml] / [kg·min],4.30,252132,DB01339,Vecuronium
,2875724,plasma clearance,The plasma clearance of vecuronium was decreased significantly (P less than 0.01) from 4.30 +/- 1.56 ml min-1 kg-1 (mean +/- SD) in normal patients to 2.36 +/- 0.80 ml min-1 kg-1 in patients with cholestasis.,Pharmacokinetics and pharmacodynamics of vecuronium in patients with cholestasis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875724/),[ml] / [kg·min],2.36,252133,DB01339,Vecuronium
,2875724,elimination half-life,The elimination half-life was of 58 +/- 22 min in normal patients and was prolonged to 98 +/- 57 min (P less than 0.05) in patients with cholestasis.,Pharmacokinetics and pharmacodynamics of vecuronium in patients with cholestasis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875724/),min,58,252134,DB01339,Vecuronium
,2875724,elimination half-life,The elimination half-life was of 58 +/- 22 min in normal patients and was prolonged to 98 +/- 57 min (P less than 0.05) in patients with cholestasis.,Pharmacokinetics and pharmacodynamics of vecuronium in patients with cholestasis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875724/),min,98,252135,DB01339,Vecuronium
,2875724,duration of effect from,A prolonged neuromuscular blockade induced by vecuronium was observed in patients with cholestasis: the duration of effect from injection to 75% recovery of the twitch height was prolonged from 74 +/- 19 min in normal patients to 111 +/- 13 min in patients with cholestasis.,Pharmacokinetics and pharmacodynamics of vecuronium in patients with cholestasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875724/),min,74,252136,DB01339,Vecuronium
,2875724,duration of effect from,A prolonged neuromuscular blockade induced by vecuronium was observed in patients with cholestasis: the duration of effect from injection to 75% recovery of the twitch height was prolonged from 74 +/- 19 min in normal patients to 111 +/- 13 min in patients with cholestasis.,Pharmacokinetics and pharmacodynamics of vecuronium in patients with cholestasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875724/),min,111,252137,DB01339,Vecuronium
,22956531,ECe(50),"The ECe(50) of propofol was 3.4 μg/mL (95% CI: 2.9, 3.7 μg/mL) with the Marsh model and 4.5 μg/mL (95% CI: 4.1, 4.8 μg/mL) with the Schnider model (P < 0.001).",The effective effect-site propofol concentration for induction and intubation with two pharmacokinetic models in morbidly obese patients using total body weight. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22956531/),[μg] / [ml],3.4,252953,DB01339,Vecuronium
,22956531,ECe(50),"The ECe(50) of propofol was 3.4 μg/mL (95% CI: 2.9, 3.7 μg/mL) with the Marsh model and 4.5 μg/mL (95% CI: 4.1, 4.8 μg/mL) with the Schnider model (P < 0.001).",The effective effect-site propofol concentration for induction and intubation with two pharmacokinetic models in morbidly obese patients using total body weight. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22956531/),[μg] / [ml],4.5,252954,DB01339,Vecuronium
,22956531,ECe(95),"The ECe(95) values were 4.2 μg/mL (95% CI: 3.8, 6.2 μg/mL) and 5.5 μg/mL (95% CI: 5.0, 7.2 μg/mL) with Marsh and Schnider models, respectively.",The effective effect-site propofol concentration for induction and intubation with two pharmacokinetic models in morbidly obese patients using total body weight. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22956531/),[μg] / [ml],4.2,252955,DB01339,Vecuronium
,22956531,ECe(95),"The ECe(95) values were 4.2 μg/mL (95% CI: 3.8, 6.2 μg/mL) and 5.5 μg/mL (95% CI: 5.0, 7.2 μg/mL) with Marsh and Schnider models, respectively.",The effective effect-site propofol concentration for induction and intubation with two pharmacokinetic models in morbidly obese patients using total body weight. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22956531/),[μg] / [ml],5.5,252956,DB01339,Vecuronium
,12403643,clearance,"Values for clearance are in the range 0.26-0.67 L/h/kg, with most studies giving a value of approximately 0.45 L/h/kg.",Pharmacokinetics and pharmacodynamics of rapacuronium bromide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403643/),[l] / [h·kg],0.26-0.67,253891,DB01339,Vecuronium
,12403643,clearance,"Values for clearance are in the range 0.26-0.67 L/h/kg, with most studies giving a value of approximately 0.45 L/h/kg.",Pharmacokinetics and pharmacodynamics of rapacuronium bromide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403643/),[l] / [h·kg],0.45,253892,DB01339,Vecuronium
,12403643,steady-state volume of distribution,A typical value for steady-state volume of distribution is 0.3 L/kg.,Pharmacokinetics and pharmacodynamics of rapacuronium bromide. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403643/),[l] / [kg],0.3,253893,DB01339,Vecuronium
,9771295,clearance,Individual clearance values during the study ranged from 1.4 to 4.4 ml kg-1 min-1.,Do the pharmacokinetics of vecuronium change during prolonged administration in critically ill patients? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9771295/),[ml] / [kg·min],1.4 to 4.4,258274,DB01339,Vecuronium
,9771295,steady-state volume of distribution,The steady-state volume of distribution (range 368-1765 ml kg-1; median 494 ml kg-1) did not change in any patient during the study.,Do the pharmacokinetics of vecuronium change during prolonged administration in critically ill patients? ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9771295/),[ml] / [kg],368-1765,258275,DB01339,Vecuronium
,9771295,steady-state volume of distribution,The steady-state volume of distribution (range 368-1765 ml kg-1; median 494 ml kg-1) did not change in any patient during the study.,Do the pharmacokinetics of vecuronium change during prolonged administration in critically ill patients? ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9771295/),[ml] / [kg],494,258276,DB01339,Vecuronium
,10690134,onset time,Mean onset time was 66 (SD 24) s.,Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),s,66,260989,DB01339,Vecuronium
,10690134,time to recovery of T1/T0,"In patients who received an antagonist 2 min after the first dose of rapacuronium, time to recovery of T1/T0 to 25% was similar after neostigmine (9.8 (3.8) min) and edrophonium (10.3 (4.3) min): in patients who received incremental doses of rapacuronium, spontaneous recovery of T1/T0 to 25% after the first dose was 18.9 (4.7) min.",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),min,9.8,260990,DB01339,Vecuronium
,10690134,time to recovery of T1/T0,"In patients who received an antagonist 2 min after the first dose of rapacuronium, time to recovery of T1/T0 to 25% was similar after neostigmine (9.8 (3.8) min) and edrophonium (10.3 (4.3) min): in patients who received incremental doses of rapacuronium, spontaneous recovery of T1/T0 to 25% after the first dose was 18.9 (4.7) min.",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),min,10.3,260991,DB01339,Vecuronium
,10690134,spontaneous recovery of T1/T0,"In patients who received an antagonist 2 min after the first dose of rapacuronium, time to recovery of T1/T0 to 25% was similar after neostigmine (9.8 (3.8) min) and edrophonium (10.3 (4.3) min): in patients who received incremental doses of rapacuronium, spontaneous recovery of T1/T0 to 25% after the first dose was 18.9 (4.7) min.",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),min,18.9,260992,DB01339,Vecuronium
,10690134,times to recovery of T4/T1 to,"In those who received an antagonist 2 min after the first dose of rapacuronium, times to recovery of T4/T1 to 0.7 were also similar after neostigmine (23.7 (7.7) min) and edrophonium (29.1 (10.7) min).",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),min,0.7,260993,DB01339,Vecuronium
,10690134,times to recovery of T4/T1 to,"In those who received an antagonist 2 min after the first dose of rapacuronium, times to recovery of T4/T1 to 0.7 were also similar after neostigmine (23.7 (7.7) min) and edrophonium (29.1 (10.7) min).",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),min,23.7,260994,DB01339,Vecuronium
,10690134,times to recovery of T4/T1 to,"In those who received an antagonist 2 min after the first dose of rapacuronium, times to recovery of T4/T1 to 0.7 were also similar after neostigmine (23.7 (7.7) min) and edrophonium (29.1 (10.7) min).",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),min,29.1,260995,DB01339,Vecuronium
,10690134,time to recovery of T1/T0,"After three incremental doses of rapacuronium, there was a longer time to recovery of T1/T0 = 25% after neostigmine compared with edrophonium (5.1 (1.0) vs 3.3 (1.3) min; P < 0.05) but more rapid recovery to T1/T0 = 75% (10.1 (2.9) vs 16.8 (10.1) min; P < 0.05) and T4/T1 = 0.7 (19.8 (6.3) vs 35.1 (10.4) min; P < 0.05).",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),min,25,260996,DB01339,Vecuronium
,10690134,time to recovery of T1/T0,"After three incremental doses of rapacuronium, there was a longer time to recovery of T1/T0 = 25% after neostigmine compared with edrophonium (5.1 (1.0) vs 3.3 (1.3) min; P < 0.05) but more rapid recovery to T1/T0 = 75% (10.1 (2.9) vs 16.8 (10.1) min; P < 0.05) and T4/T1 = 0.7 (19.8 (6.3) vs 35.1 (10.4) min; P < 0.05).",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),min,5.1,260997,DB01339,Vecuronium
,10690134,time to recovery of T1/T0,"After three incremental doses of rapacuronium, there was a longer time to recovery of T1/T0 = 25% after neostigmine compared with edrophonium (5.1 (1.0) vs 3.3 (1.3) min; P < 0.05) but more rapid recovery to T1/T0 = 75% (10.1 (2.9) vs 16.8 (10.1) min; P < 0.05) and T4/T1 = 0.7 (19.8 (6.3) vs 35.1 (10.4) min; P < 0.05).",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),min,3.3,260998,DB01339,Vecuronium
,10690134,recovery to T1/T0,"After three incremental doses of rapacuronium, there was a longer time to recovery of T1/T0 = 25% after neostigmine compared with edrophonium (5.1 (1.0) vs 3.3 (1.3) min; P < 0.05) but more rapid recovery to T1/T0 = 75% (10.1 (2.9) vs 16.8 (10.1) min; P < 0.05) and T4/T1 = 0.7 (19.8 (6.3) vs 35.1 (10.4) min; P < 0.05).",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),min,75,260999,DB01339,Vecuronium
,10690134,recovery to T1/T0,"After three incremental doses of rapacuronium, there was a longer time to recovery of T1/T0 = 25% after neostigmine compared with edrophonium (5.1 (1.0) vs 3.3 (1.3) min; P < 0.05) but more rapid recovery to T1/T0 = 75% (10.1 (2.9) vs 16.8 (10.1) min; P < 0.05) and T4/T1 = 0.7 (19.8 (6.3) vs 35.1 (10.4) min; P < 0.05).",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),min,10.1,261000,DB01339,Vecuronium
,10690134,recovery to T1/T0,"After three incremental doses of rapacuronium, there was a longer time to recovery of T1/T0 = 25% after neostigmine compared with edrophonium (5.1 (1.0) vs 3.3 (1.3) min; P < 0.05) but more rapid recovery to T1/T0 = 75% (10.1 (2.9) vs 16.8 (10.1) min; P < 0.05) and T4/T1 = 0.7 (19.8 (6.3) vs 35.1 (10.4) min; P < 0.05).",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),min,16.8,261001,DB01339,Vecuronium
,10690134,T4/T1,"After three incremental doses of rapacuronium, there was a longer time to recovery of T1/T0 = 25% after neostigmine compared with edrophonium (5.1 (1.0) vs 3.3 (1.3) min; P < 0.05) but more rapid recovery to T1/T0 = 75% (10.1 (2.9) vs 16.8 (10.1) min; P < 0.05) and T4/T1 = 0.7 (19.8 (6.3) vs 35.1 (10.4) min; P < 0.05).",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),min,0.7,261002,DB01339,Vecuronium
,10690134,T4/T1,"After three incremental doses of rapacuronium, there was a longer time to recovery of T1/T0 = 25% after neostigmine compared with edrophonium (5.1 (1.0) vs 3.3 (1.3) min; P < 0.05) but more rapid recovery to T1/T0 = 75% (10.1 (2.9) vs 16.8 (10.1) min; P < 0.05) and T4/T1 = 0.7 (19.8 (6.3) vs 35.1 (10.4) min; P < 0.05).",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),min,35.1,261003,DB01339,Vecuronium
,10690134,clearance,"Typical values for clearance and initial volume of distribution (V1) were 4.4 ml kg-1 min-1 and 94.8 ml kg-1, respectively.",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),[ml] / [kg·min],4.4,261004,DB01339,Vecuronium
,10690134,initial volume of distribution (V1),"Typical values for clearance and initial volume of distribution (V1) were 4.4 ml kg-1 min-1 and 94.8 ml kg-1, respectively.",Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690134/),[ml] / [kg],94.8,261005,DB01339,Vecuronium
,10201669,weight-normalized plasma clearance,"Rapacuronium's weight-normalized plasma clearance was 7.03 x (1 - 0.0507 x (HgB - 13)) ml x kg(-1) x min(-1), where HgB is the patient's preoperative value for hemoglobin (g/100 ml); however, rapacuronium's blood clearance (11.4+/-1.4 ml x kg(-1) x min(-1), mean +/- SD) did not vary with hemoglobin.",Factors affecting the pharmacokinetic characteristics of rapacuronium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201669/),[ml] / [kg·min],7.03 x,270195,DB01339,Vecuronium
,10201669,blood clearance,"Rapacuronium's weight-normalized plasma clearance was 7.03 x (1 - 0.0507 x (HgB - 13)) ml x kg(-1) x min(-1), where HgB is the patient's preoperative value for hemoglobin (g/100 ml); however, rapacuronium's blood clearance (11.4+/-1.4 ml x kg(-1) x min(-1), mean +/- SD) did not vary with hemoglobin.",Factors affecting the pharmacokinetic characteristics of rapacuronium. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201669/),[ml] / [kg·min],11.4,270196,DB01339,Vecuronium
